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METAL CONTAINING NUCLEOSIDES THAT FUNCTION AS THERAPEUTIC
AND DIAGNOSTIC AGENTS AGAINST
BRAIN CANCER

JENNIFER NICOLE WILLIAMS

ABSTRACT
Nucleoside transporters are essential components for the hyperproliferative
capabilities of brain cancer cells. These transporters play important roles to increase
nucleoside metabolism which is necessary for higher levels of DNA and RNA synthesis.
The goal here is to use a series of metal containing nucleoside (MCN) analogues as novel
chemical agents to study how nucleosides are imported into cells. In addition, we expect
that these MCNs will ultimately function as therapeutic and/or diagnostic agents for brain
cancer. Concentrative nucleoside transporters (CNTs) and equilibrative nucleoside
transporters (ENTs) represent the two classes of transporters that allow MCNs to travel in
(and out) of brain cancer cells. This study focuses on cyclometalated iridium nucleosides,
designated Ir(III)-PPY, Ir(III)-BZQ, and Ir(III)-PBO, that were tested on a glioblastoma
brain cancer cell line, U87. The therapeutic activities of these MCNs were tested against
U87 glioblastomas using several biochemical methods.

Cell viability experiments

demonstrate that all compounds induce cell death in a time- and dose-dependent manner.
Ir(III)-BZQ was identified as the most potent MCN, exhibiting an effective concentration
(EC50) of 10 µM after 48 hours of exposure.
viii

The collective photophysical properties of these fluorescent MCNs were also used
to visualize their intracellular distribution throughout localized regions of the cell.
Fluorescent microscope images reveal the accumulation of Ir(III)-BZQ in the cytosol after
4 hours of exposure while significant nuclear localization is detected at longer times (~24
hours). This timing corresponds with the onset of cell death and provides insight into the
mechanism of action of these MCNs. In addition, the cellular uptake and cytotoxicity of
Ir(III)-BZQ is significantly reduced when U87 cells are pretreated with the natural
nucleoside, adenosine. Collectively, the ability to measure the uptake of MCNs coupled
with their anti-cancer activities define these novel nucleoside analogues as “theranostic
agents” – compounds that possess both therapeutic and diagnostic activities.
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CHAPTER I
INTRODUCTION TO CANCER, CHEMOTHERAPY AND DIAGNOSTICS

1.1

Cancer Incidence

Cancer is the second leading cause of death in industrialized countries such as the
United States and ranks second only to cardiovascular disease. It is estimated that one in
every four people in the United States will develop cancer during their lifetime.(1)
In 2014, it is estimated that approximately 1.4 million people will be diagnosed with some
form of cancer.(2)

This disease affects all segments of society. In this respect, all

races and age groups are susceptible to cancer. Despite over 60 years of basic and clinical
research in oncology, there is still no cure for this insidious disease. As described below,
individuals who are afflicted with cancer typically undergo several different treatments
ranging from surgery, exposure to ionizing radiation, or treatment with various
chemotherapeutic agents. The focus of this thesis is toward studying the anti-cancer effects
of metal-containing nucleosides as a new class of chemotherapeutic agents.

1

1.2

Cancer as a Hyperproliferative Disease

Cancer is a mutli-faceted disease that can arise from a number of inter-related
causes that include self-sufficiency in growth signals, resistance to anti-growth stimuli,
evasion of apoptosis, sustained angiogenesis, and invasion/metastatic potential.(3)
However, one of the most recognizable features of most cancers is limitless replicative
potential in which their hyperproliferative nature is characterized by uncontrollable DNA
synthesis. This feature provides an important focal point for therapeutic intervention.
One major target and biomarker for chemotherapeutic intervention is the
characteristic increased production of DNA intrinsic to the hyperproliferative reproduction
of cancer cells.(4)

As new therapeutic targets continue to be revealed, cell death can

now be achieved in several mechanistic ways within hyperproliferative, cancer cells. This
intricate process of cell growth and preparation for reproduction is regulated by numerous
checkpoints monitoring completion and accuracy of critical cellular events. Consequently,
proper progression onto the next phase of the cell cycle is dependent upon successful
completion of the events involved in the current phase once a checkpoint is reached.(5)
As new cells grow in your body via the normal process of cell division called mitosis, old
cells die naturally via the process called apoptosis.(6)

Cancer is amongst many

different types of diseases that are a result of the hyperproliferative capabilities of
malfunctioning cells, causing uncontrolled cell growth.(7) (4)

As this cycle

continues in cancer cells, the cell’s ability to adhere to or recognize signals that tell it to
grow, differentiate or die is somehow diminished.(8)

Understanding cancers and

many other diseases is heavily dependent on identifying the molecular pathways that lead
2

to a loss of cell cycle regulation. When does this loss of function lead to cancer? There
are a vast number of elements a cell requires or encounters within its lifespan that can be
used as targets to develop chemotherapeutic agents and better understand these intricate
cellular processes.
When the cellular process of mitosis (M-phase) ends and cytokinesis has produced
a new cell, one revolution of the cell cycle is complete. The new cell produced will
eventually begin to grow in size (G1-phase).

Once the cell has carried out specific

instructions imbedded within its DNA blueprint, it eventually initiates the synthesis of
more DNA (S-phase) before it finalizes its duties in the late phase of its life (G2-phase). A
normal cell should have doubled its DNA before it is finally ready to enter mitosis (Mphase).(9)

Cells that are damaged during the cell cycle will undergo apoptosis if the

cell cannot be repaired during the G2-phase.

Apoptosis
When cells become defective, damaged beyond repair or are deemed unnecessary
for developmental purposes, they undergo the process of programmed cell death known as
apoptosis. In addition to their hyperproliferative capabilities, one of the hallmarks of
cancer cells is their ability to evade apoptotic cell death. Because cancer cells lose this
critical capability, damaged cells continue to proliferate uncontrollably. This can directly
lead to the accumulation of damaged cells that can become more and more abnormal. DNA
damage associated with hyperproliferation and signaling imbalances resulting from
elevated levels of oncogene signaling are amongst the most notable apoptosis-inducing
stresses.(10)

Once the cell has unsuccessfully attempted a repair mechanism to correct
3

the damage, an orderly process of signals are produced to instruct the cell to commit the
cellular version of suicide. During this process, cell morphology changes as the cell begins
to shrink in size as their chromatin condenses. The apoptotic cell’s membrane remains
intact as the cell is phagocytosed in vivo and its counterparts are recycled. This process is
contrary with the necrotic form of cell death associated with inflammation and cellular
swelling followed by ruptured membranes and cell lysis.
There are two major signaling mechanisms that exist for the activation of apoptosis
(extrinsic and intrinsic) that can be distinguished by their physiological pathways and
biochemical factors. Extrinsic apoptosis, or death receptor-mediated apoptosis, may or
may not engage the intrinsic apoptotic, which is a Bcl-2 family-regulated pathway targeting
the mitochondria.(11)

During the intrinsic apoptotic pathway cell death may be

triggered through DNA damage or severe cell stress such as hypoxia and limited quantities
of growth factor and/or nutrients. As the mitochondrial exterior membrane increases in
permeability, pro-apoptotic molecules such as cytochrome c are released from the
mitochondria into the cytosol. Following activation, additional intracellular pro-apoptotic
proteins are released to activate caspases that ultimately results in apoptosis.
The extrinsic pathway is activated in response to diverse external cellular signals
and death receptors on the surface of the plasma membrane such as the class of tumor
necrosis factor receptors (TNFR).(12)

As ligands bind to these receptors, the extrinsic

apoptotic pathway is activated by the formation of the “death inducing signaling complex”
(DISC) resulting in the initiation of the caspase cascade through caspase 8.(13)

The

extrinsic apoptotic pathway also has the potential to induce tumor cell death independently
of the intrinsic pathway.(14)

Studying the interactions of proteins involved in both
4

pathways of apoptosis, intrinsic and extrinsic, will further advance the development of
novel molecules for the treatment of apoptosis-related diseases such as cancer. (15)

1.3

Current Chemotherapeutic Agents

Indeed, there are a wide variety of therapeutic agents that inhibit DNA synthesis
which is ultimately responsible for cellular proliferation (Figure 1).

Some

chemotherapeutic agents are designed to interact with various checkpoints within the cell
cycle that inhibit DNA synthesis taking place during the synthesis phase (G1/S-phase) of
the cell cycle. These are known as cell-cycle specific agents and represent a large
percentage of the two major classes of specific and cell cycle non-specific
chemotherapeutic agents.(16)

One example of a cell cycle specific agent is

staurosporine. Studies by Bruno and Ardelt show that leukemia Molt-4 cells treated with
staurosporine were arrested in the G2-phase of the cell cycle.(17)

Although DNA

replication continued and reflected clear changes in nuclear morphology, the treated cells
did not undergo cell division. Staurosporine was found to induce classical apoptosis in
some cancerous cell lines and inhibit cell proliferation in a time- and dose-dependent
manner by up to 90%.(18)

It is most effectively used today against cancers with an

overexpression of PKC, such as colon cancer. Further research identified it as a potent
inhibitor of protein kinase-C (PKC), one of the various cyclin-dependent kinases that
coordinates progression within the cell cycle.(16)

5

Figure 1. Many anti-cancer agents are cell-cycle specific as they are deigned to inhibit
selective targets associated with efficient cell-cycle progression.(16)

6

Naturally occurring chemotherapeutics like the plant alkaloids taxol and vincristine
are also amongst cell cycle specific chemotherapeutic agents.(19)

These drugs are

designed to target the mitosis phase (G2/M-phase) of the cell cycle by causing the inhibition
of microtubule organelles and preventing the formation of mitotic spindles.(16)

This

causes a cell to eventually self-terminate once the excessive amount of DNA present after
cellular preparation for division causes a signal to be produced that now identifies this
specific cell as an abnormal or mutagenic cell. Further programming then instructs the
cell to initiate termination via the normal cell death process (apoptosis). Analogs such as
vinblastine, vinblastine, docetaxel and other naturally occurring alkaloids (matrine and
oxymatrine) have also shown anti-cancer potentials as cell cycle arrest agents, not to
mention their known ability to possess anti-inflammatory, anti-fibrotic and anti-allergic
effects.(20)
Cell cycle non-specific agents, on the other hand, work by directly targeting the
DNA polymerization process and its enzymes in order to damage/alter the structure of
nucleic acids and base-pairs within DNA genes. Few chemotherapy drugs used today can
compare to the success of the DNA-damaging platinum complexes, such as cisplatin and
its derivatives.

By forming stable DNA adducts and crosslinking lesions between

nucleobase and spatially close residues that inhibit the function of DNA polymerases, these
DNA damaging agent causes an apoptotic induced cell death.(16, 21)

Despite its

efficacy against solid tumors, the development of less toxic analogs and other metal
derivatives of cisplatin has resulted in equiactive complexes such as carboplatin and
iproplatin.(22)

Therapeutic resistance to cisplatin has also been a driving factor in

the development of numerous anti-cancer analogs including oxaliplatin, nedaplatin,
7

heptaplatin, lobaplatin and an extensive library of other platinum based derivatives.(23, 24)
Other examples of DNA damaging agents include therapeutic agents such as chlorambucil,
and cyclophosphamide also generate crosslinked lesions in DNA that prevent movement
of the DNA polymerase.(25-29)

Nucleoside Analogs Used as Therapeutic Agents
Anti-metabolites are another type of cell-cycle non-specific chemotherapeutics and
perhaps the largest class of anti-neoplastic agents that can produce multiple effects on DNA
synthesis. In this respect, nucleoside analogs are a promising type of antimetabolites that
represent essential components for treating many lymphoproliferative disorders and some
solid tumors. There are currently eleven FDA approved nucleoside analogs that account
for ~20% of all drugs used in chemotherapy.(30)

The structures for several of

the most commonly used nucleoside analogs as well as their natural counterparts are
provided in Figure 2. The primary pharmacological effect for nucleoside analogs is
identical as they function as classic chain-terminators of DNA synthesis. However,
nucleoside analogs are often subdivided into two distinct classes. The first class resembles
purine nucleosides while the second resemble pyrimidine nucleosides. This distinction is
not only based on differences in their chemical composition but also on differences
observed in their pharmacodynamic and pharmacokinetic behavior.
Unlike the purine analogs listed above, many chemotherapeutic nucleoside analogs
also contain recognizable pyrimidine moieties that promote transport across the cell
membrane. Pyrimidine analogs such as gemcitabine and decitabine have also produced
8

promising improvements in the treatment of pancreatic cancer and some solid tumors.(3133)

transport. For example, the pyrimidine analog, cytarabine, displays a higher

degree of toxicity against replicating cells compared to quiescent cells since it is primarily
utilized during the S phase of the cell cycle.(34)

In contrast, purine analogs such

as fludarabine and cladribine often display more cytotoxic effects against slowly
replicating cells such as indolent lymphoma as these analogs can be incorporated into DNA
during double strand DNA repair.(35-38)
The use of a modified sugar such as an arabinose sugar opposed to a deoxyribose
is a common example augmentation in analogs, as seen in in Figure 2.(39-41)
Synthetic strategies in modification of the base or sugar moiety of the nucleoside continue
to be investigated and support the need for developing new nucleoside analogs that have
increased efficacy against solid tumors.
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The purine nucleoside analogs used most commonly used modern chemotherapy
include

fludarabine

chlorodeoxyadenosine

(9-β-D-arabinoside-2-fluoroadenine
(2′-CdA)),

clofarabine

(FA)),

cladribine

(2-

(2-chloro-9-(2'deoxy-2'-

fluoroarabinofuranosyl)adenine), and pentostatin ( 2′-deoxycoformycin) (Figure 2).(4244)

These nucleoside analogs exert near exclusive cytotoxic effects against

hematological malignancies such as chronic lymphoblastic leukemia (CLL), nonHodgkin’s lymphomas, Waldenström’s macroglobulinemia, and cutaneous T-cell
lymphoma.(45-48)

2-CdA and pentostatin are noteworthy for their widespread use

against hairy cell leukemia.(49, 50)

These analogs possess chemical structures

that are similar to (deoxy)adenosine. For example, the structure of 2-CdA differs from
deoxyadenosine by the simple replacement of hydrogen with chlorine at the second
position of the purine ring. Fludarabine is a halogenated analog of adenosine in which
fluorine is introduced at the second position of the adenine ring. Clofarabine is similar to
cladribine as the hydrogen in the 2-position of the purine is replaced with chlorine.
However, the deoxyribose moiety in cladribine contains a fluorine atom at the 2'-position.
Pentostatin is a structural analog of deoxyadenosine that inhibits adenosine deaminase and
thus exerts cytostatic and cytotoxic effects by disrupting nucleoside and nucleotide
metabolism.(51, 52)

1.4

Problems Associated with Anti-Cancer Agents

A major disadvantage of nearly every chemotherapeutic treatment is the fact that
anti-cancer drugs also harm normal, healthy cells that share the same characteristic of fast
11

reproduction, such as hair, blood, bone marrow, reproductive and gastrointestinal cells.
This leads to the common symptoms generally associated with chemotherapy such as
nausea, fatigue, hair loss, vomiting, anemia and immune system suppression.(53-55)
A quantitative measure that is often used to gauge the potential safety of a drug is
its therapeutic index which is calculated as the concentration of drug that produces 50% of
a therapeutic response compared to the concentration that elicits 50% of a toxic or adverse
response.(56)

TI can be further simplified as “the ratio of the dose that produces a

toxic effect in 50% of a treated population (TD50) divided by the dose that produces a lethal
effects in 50% of the population (LD50)”. (57)

When plotted, the ED50 and ID50 differ in

their formation of the resulting sigmoidal curve. ED50 results in an up-hill dose response
curve that plots and increased response. The ID50 resulting curve, on the other hand, is a
down-hill dose response curve that plots and inhibitory response. However, in this study
the terms EC50, IC50, ED50 and ID50 can been used interchangeably, opposed to LD50 and
TD50. In animal studies, the therapeutic index is the lethal dose of a drug for 50% of the
population (LD50) divided by the minimum effective dose for 50% of the population
(ED50). The dose that produces a toxicity in 50% of the population (TD50) is used to
calculate the therapeutic index.in human clinical trials; instead, of lethality. Due to the
sever toxicities that occur with the administrating sublethal doses in humans, the lethal
dose is generally reserved for determination in animal studies. Because there are usually
severe toxicities that occur at sublethal doses in humans, these toxicities often limit the
maximum dose of a drug.(58)
Figure 3 provides a graphical representation of therapeutic index in which the
beneficial and toxic effects of a drug are plotted as a function of variable drug
12

concentrations. According to a therapeutic index plot, the pictorial representation of a drug
declared highly unsafe would show a narrow gap between the two curves generated based
on the doses plotted that represent the desired therapeutic effects and the doses plotted
representing a toxic effects. Although lethal dose values are usually obtained in vitro or
by laboratory animal studies, each variable in determining the therapeutic index represents
a critical component when administering chemotherapeutics.
As discussed above, the therapeutic index for many anti-cancer drugs is extremely
low. Values for therapeutic index can be as low as1.5 to 5 for compounds such as 5fluorouracil, cisplatin, and temozolomide.(59, 60)

In this thesis, I define the

potential therapeutic index for two (2) new metal-containing nucleosides by measuring
their cell-killing effects against hematological and adherent cancer cell lines versus noncancerous cell lines such as human fibroblasts.
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Figure 3. Therapeutic index (TI), which is defined as the ratio between the TD50 and
ED50 (TI=TD50/ED50) is determined by measuring the frequency of desired responses
and toxic responses as a function of variable drug concentrations.

14

1.5

Cancer Diagnosis

Many types of tumors can be visualized by molecular imaging techniques such as
molecular resonance imaging (MRI), computed tomography (CT), positron emission
tomography (PET), single-photon-emission computed tomography (SPECT), and
ultrasonography (US). A surgical biopsy (a small extraction of the tumor that is analyzed
by a pathologist under a microscope) will usually provide the most accurate diagnosis.
This can either be performed during surgical resection or as a separate diagnostic
procedure.(61-63)

1.5.1 Molecular Detection of Cancer using Diagnostic Biomarkers and Agents

The presence of a tumor as well as its progression can be identified by monitoring
the abnormal signals and/or anatomical characteristics that resutls from changes in various
metabolic and signaling pathways that occur in cancer cells. Signals generated from the
tumor itself or from irritation associated with the surrounding tissue can produce defined
biomarkers that help doctors profile the cancer predisposition and state of
development.(64)

A biomarker is defined as a characteristic within a cell that is

objectively measured as an indicator of normal biological processes, pathogenic processes
or

pharmacological

response

to

some

form

of

therapeutic

intervention.(65)

For example, glucose metabolism in cancer cells is significantly different compared to
normal cells, and this difference represents an important biomarker for the detection of
several types of cancer.
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The physiological changes associated with the fermentation of glucose in the
absence of oxygen in cancer cancers, commonly known today as the Warburg Theory of
Cancer,

represents a biomarker that can be easily detected by clinicians when cancer is

present.

The increase in glucose uptake associated with this change in cancer cell

metabolism can monitored using 2’-deoxy-2’-(18F) fluoro-D-glucose (18F-FDG) as a
surrogate for glucose.(66)
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F-FDG is considered the gold standard amongst all

radioactive tracers used in the detection of cancer.(67)

At the molecular level, the

substitution of a fluorine-18 atom for the hydroxyl group in the 2’ position of glucose, the
radioactive tracer 18F-FDG can reveal specific physiological changes in the metabolism of
this glucose analog during positron emission tomography (PET) scans. The information
resulting from the PET scan can be further quantified and manipulated to produce 3-D
images of a tumor. As a result, an oncologist can define the location of most tumors as well
as measure changes in mass that can occur in the absence and presence of treatment with
therapeutic agents.
While 18F-FDG is widely used to detect many types of cancer, its utility in brain
cancer is limited since the uptake in normal brain tissue is considerably high. As such, it is
nearly impossible to distinguish cancerous tissue from normal brain tissue due to low
signal-to-noise-ratios. As a result alternative approaches and methods must be used to
identify brain cancers effectively on a rapid time scale. Glioma and glioblastomas
neoplasms are considered to be amongst the most aggressive brain tumors with the highest
severity, resulting in a terminal cancer known as glioblastoma multiforme (GBM).(63)
There are several biomarkers that are used to identify for GBM. These include the loss of
heterozygosity (LOH) of specific chromosomes as well as promoters such as O(6)16

methylguanine-DNA-methyltransferase (MGMT), which is the enzyme primarily
responsible for removing DNA lesions caused by alkylating agents.(68, 69)
The limitations of biomarkers and current macroscopic imaging systems, however, often
require them to be coupled to more advanced molecular probes and imagery forms to
produce diagnostic platforms with increased spatial resolution and obtain molecular
information that will enable the development of new imaging probes.(70)

1.5.2 The Need for Improved Diagnostic Agents to Detect Brain Cancer

Rapid diagnosis of cancer is essential for properly treating this disease. Indeed, it
is well-recognized that early detection and diagnosis of cancer is key to generating better
patient responses, most notably in reducing mortality rates. In fact, rapid and accurate
diagnosis of cancer is now considered as important as the drugs used to treat this disease.
This is especially true with brain cancers including glioblastoma. Brain tumors are the
second-largest killer of children and patients under the age of 34.(1)

In 2009 alone,

there were approximately 190,000 individuals with brain tumors reported across the globe.
Of these reported cases, over 140,000 died as a result of their brain cancer.(71)

In

the United State alone, approximately 20,000 individuals with brain cancers die annually.
These epidemiological reports emphasize the incredible high mortality rate for most brain
cancers. However, an even more alarming feature is the rapid rate of death in patients with
brain cancers. Specifically, only 13% of brain cancer patients live beyond 12 months after
diagnoses, and only a mere 2% of patients live longer than two years.(72)
Because of the hyper-proliferative nature intrinsic to all malignant cancer cells, it can often
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be only a matter of months between when a tumor is detected and when it has reached a
size that causes death.
Because the brain is compartmentalized, a person is generally diagnosed with brain
cancer only after significant symptoms begin to appear. These symptoms, described below,
are usually directly related to the location and size of the tumor. For example, a person
with a brain tumor might experience headaches or a lack in cognitive ability. A loss in
vision, on the other hand, might indicate that the tumor is located near the occipital or
frontal lobes of the brain that control vision. Emotional and behavioral changes such as
difficulty speaking or swallowing and uncoordinated gait (a.k.a. “walking-on-a-boat
syndrome”) are also symptoms that would be associated with a tumor being located within
the brainstem.(73)

Glioma and Glioblastoma Multiforme Tumors (GBM)
Within the central nervous system (CNS), nerve cells, or neurons, and glial cells
are the main two types of cells that comprise brain matter. Derived from the Greek word
for “glue”, glia or glial cells outnumber neurons in the brain ten to one.(74)

A single

neuron does not function individually amongst the billions of neurons in the human brain.
Instead, a complex network of interconnection between neurons and glial cells enables a
single neuron to directly communicate with thousands of other neurons and transmit
electrical and/or chemical signals.(74)

Together, these cell counterparts make up the

functional areas of the brain divided into the regions commonly known as the cerebellum,
brainstem, motor and sensory strips and the frontal, temporal, occipital and parietal lobes
or regions of the brain.(75)
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Amongst glia, four major types of glial cells within the brain are key for the
successful function and transmission of information within the brain. Astrocytes,
oligodendrocytes, microglial cells and ependymal cells each play specific roles within the
central nervous system (Figure 1). Astrocytes help protect the brain by their formation of
the blood brain barrier via surrounding capillary blood vessels within the brain. These tight
junctions formed by adjacent astrocytes create the barrier that restricts hydrophilic
molecules and other constituents within the blood stream from entering the brain.
Oligodendrocytes play an important role in the transfer of information from the neuron’s
cell body (soma) down the axon and on to the axon terminal. Adhering to the surface of
the axon “tail” of the neuron, oligodendrocytes also increases the ability of axons to
transmit signals quickly. Microglial cells help rid the brain of dead, damaged or old cells,
while ependymal cells are found at the junctions between the brain and the protective,
nutrient rich cerebrospinal fluid (CSF). Unlike glial cells, neurons do not have the ability
to undergo cell division. Therefore, neurons typically only develop within children and
although new neurons can be produced in adults (such as learning a new language), once
these quiescent cells die, they cannot be replaced. This is the reason why nearly all brain
tumors such as Glioblastoma Multiforme (GBM) represents a type of cancer of the glial
cells.
Glioma and glioblastomas neoplasms are considered to be amongst the most
aggressive brain tumors with the highest severity.(63)

The terms glioma and/or

glioblastoma represent a class of malignant tumors associated with the central nervous
system (CNS) and particularly the brain and spinal cord. These primary tumors can be
further separated into slow growing, benign tumors and faster growing, more severe
19

malignant tumors. To date, the pathogenesis and initiating factors that turn these normally
functioning brain cells into hyperproliferative cancer cells remains unclear.
In general, the formation of malignant neoplasms in the confined area of the skull
causes added pressure that can in turn lead to numerous side effects ranging in severity
from harmless to lethal. Additionally, each individual case differs from patient to patient.
With incredibly low survival rates for patients, early detection is often the best hope for
treating glioblastoma tumors. The lack of effective chemical entities to detect this type of
cancer drives the need for improved diagnostic agents for brain cancer patients.(71)
In this thesis, I interrogate the use of novel fluorescently-labeled nucleoside analogs as a
spectroscopic probe to detect brain cancer cells. This approach is based on the hypothesis
that the hyperproliferative nature of brain cancer cells necessitates the requirement for high
levels of nucleosides needed for DNA and RNA synthesis. My research will use metalcontaining nucleosides as fluorescent surrogates to visualize uptake into brain cancer cells
and compare that towards uptake in non-cancerous fibroblasts.

Because of their

nucleoside analog structure, metal containing nucleosides should surpass the limited
capability of other chemotherapeutics that are not suitable for brain cancer because they
cannot pass the blood brain barrier. I hypothesize that there will be a difference in the
uptake in these metal-containing nucleosides, and these results will provide initial evidence
to further evaluate using these analogs as potential diagnostic probes for cancer detection.
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1.6

The Role of Nucleoside Transporters in Normal Cell Homeostasis

Nucleosides and their corresponding nucleotides play important roles in cell
physiology by functioning as both nutrients and modulators of cellular homeostasis. For
example, nucleoside triphosphates such as ATP and GTP are widely used as energy sources
for various biological reactions.(76, 77)

In addition, nucleosides participate as

ligands for purinergic receptors and transducers of endocrine signals and thus modulate a
wide variety of cellular events. Adenosine is a particularly important inflammatory
modulator as increased extracellular adenosine levels activate the A2a receptor on the cell
surface of immune cells.(78-81)

Finally, nucleosides are the monomeric building

blocks of DNA and RNA and thus play central roles in the storage and expression of genetic
information.
In general, regulating the intra- and extracellular concentration of nucleosides
influences important physiological processes ranging from cardiovascular activity to
neurotransmission to cellular proliferation.(82)

Nucleoside and nucleotide

biosynthesis are energetically costly processes and thus generally restricted to selected cell
types.(83)

In fact, it is more efficient for cells to obtain essential nucleosides

through salvage and/or nucleoside recycling pathways than through de novo synthesis. As
such, the first and arguably most important step in nucleoside metabolism is transporting a
nucleoside past the plasma membrane (Figure 4). Since nucleosides and nucleotides are
rather hydrophilic, they show negligible permeability across hydrophobic cellular
membranes. To facilitate uptake, cells use specific proteins to efficiently translocate
nucleosides from the extracellular milieu into the cytosol. There are two types of cellular
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nucleoside transport - an equilibrative transport mechanism that shows broad specificity
but relatively low affinity for substrates, and a Na+-dependent, concentrative and high
affinity transport process that exhibits some substrate specificity (Figure 4). These two
types of nucleoside transport processes are catalyzed by classes of membrane-bound
proteins designated as concentrative (CNT) or equilibrative nucleoside transporters (ENT).
The human ENT family of membrane proteins is represented by four members (designated
hENT1-4) that contain a predicted protein topology of 11 transmembrane helices.(84, 85)
The best-characterized members of the family, hENT1, hENT2, and hENT3 show similar
broad selectivities for purine and pyrimidine nucleosides.(86, 87)
hENT2 and hENT3 differ as they can also transport nucleobases.(88)

However,
hENT4

is unique in its selectivity for adenosine and its ability to transport a variety of organic
cations.(89)
There are three subtypes of hCNT transporters that contain 13 transmembrane
domains as opposed to 11 transmembrane helices found in hENTs.(90, 91)

While

all three CNTs are Na+-dependent, they differ in nucleoside specificity. For example,
hCNT1 prefers pyrimidine nucleoside transport, hCNT2 is purine preferring, and hCNT3
shows broad substrate specificity. In general, CNT family members display Km values for
measuring nucleosides that are ~10-fold lower than those displayed in ENT family
members.(92)
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Figure 4. There are two types of cellular nucleoside transport, an equilibrative
transport mechanism and a concentrative transport mechanism.
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1.7

The Role of Nucleoside Transporters in Cancer Chemotherapy

The therapeutic activity of many nucleoside analogs used as anti-cancer agents is
often limited by their cellular uptake and subsequent metabolism to the corresponding
nucleoside triphosphate. In particular, the hydrophilic nature of most nucleoside analogues
requires an active transport system to catalyze efficient cellular uptake. Indeed, the cellular
levels of nucleoside transporters can be used as predictive factors for patient responses, as
seen with the nucleoside analog gemcitabine against pancreatic cancer and lung
disease.(32, 93, 94)

For example, Fludarabine is a prodrug that must first be

converted from the monophosphate form to the free nucleoside, F-ara-A, prior to gaining
cellular entry. This conversion is catalyzed by 5-nucleotidase and occurs readily in
plasma.(35, 95)

After dephosphorylation, the free nucleoside must enter the cells

via the action of one of several nucleoside transporters.
Once inside the cell, most purine nucleosides accumulate mainly as the
corresponding 5′-triphosphate. In the case of F-ara-A, the rate-limiting step in the
formation of triphosphate is conversion of F-ara-A to its monophosphate which is catalyzed
by deoxycytidine kinase.(96, 97)

Although F-ara-A is a poor substrate for

this pyrimidine kinase, the high specific activity of this enzyme in lymphoid tissues results
in overall efficient phosphorylation. The monophosphate is converted to the diphosphate
by AMP kinase, and then to the corresponding triphosphate by nucleoside diphosphate
kinase.(98)
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1.8

Applying Metal-Containing Nucleosides as Diagnostic Agents

Since nucleoside transporters play key roles in mediating the uptake of several
nucleoside analogs that function as anti-cancer agents, it is important to develop chemical
entities that can accurately and easily measure their individual and composite activities at
the cellular and organismal level. Most contemporary approaches quantify cellular uptake
by using isotopically-labeled nucleosides. This reliance unfortunately produces several
logistical problems such as special requirements for synthesis and the use of discontinuous
time-based assays to monitor nucleoside influx and/or efflux.(99, 100)

Finally, the

use of radiolabeled nucleosides has obvious limitations toward measuring nucleoside
transport and tissue distribution in humans.
To combat these deficiencies, the Berdis lab recently developed a metal-containing
nucleoside analog designated, Ir(III)-PPY nucleoside. This novel analog contains iridium
embedded within a bis-cyclometallated scaffold attached to a deoxyriboside (Figure
5).(101, 102)

The design of this metal-containing nucleoside was driven by several

factors. First, it is well-established that cyclometalated complexes are highly stable and
thus are capable of withstanding the aqueous environment of a living cell.(103, 104)
Secondly, these complexes are phosphorescent luminophores that emit light.(105)

A

particularly interesting feature is that they are subject to rational tuning to emit visible light
across a range of wavelength. In this case, triplet luminescence arises from either a metalto-ligand charge-transfer (MLCT) state or a ligand-centered excited state.(106-113)
Metal containing nucleosides should surpass the limited capability of other
chemotherapeutics that are not suitable for brain cancer because they cannot pass the blood
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brain barrier.

Finally, the attachment of a deoxyribose moiety to bis-cyclometallated

scaffold was predicted to enhance cellular import via the activity of one or more nucleoside
transporters.
The Berdis lab used Ir(III)-PPY nucleoside as a prototypical metal-containing
nucleoside to generate several lines of biochemical evidence indicating that this metalcontaining nucleoside functions as a “theranostic agent”, i.e., a compound that possesses
both therapeutic and diagnostic activity against cancer cells. In particular, cell-based
studies revealed that Ir(III)-PPY nucleoside produces anti-cancer effects against the
cervical cancer cell line, KB3-1. In addition, the metal-containing nucleoside rapidly
enters cells via the activity of a specific nucleoside transporter designated hENT1.
Finally, co-localization studies using high-field microscopy techniques demonstrated
that Ir(III)-PPY nucleoside accumulates in the nucleus and mitochondria of these cancer
cells. This last feature indicates that the metal-containing nucleoside is a novel chemical
probe that can measure nucleoside distribution at the cellular level. The goal of this
thesis is to extend these findings and further test the ability of Ir(III)-PPY nucleoside
and other related analogs to function as “theranostic” agents against brain cancer.
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Figure 5. Structural comparison of the two metal containing nucleosides (MCNs)
primarily used in this work.
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CHAPTER II
PHARMACOLOGICAL STUDIES EVALUATING THE THERAPEUTIC
ACTIVITY OF METAL-CONTAINING NUCLEOSIDES AGAINST BRAIN
CANCER CELLS

2.1

Abstract

Nucleoside transport is an essential process that helps maintain the
hyperproliferative state of most cancer cells. As such, this process represents an important
target for developing therapeutic agents to treat cancer. This chapter integrates the ability
of two metal-containing nucleosides, Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside,
to produce anti-cancer effects the human brain cancer cell line, U87. The anti-cancer effects
of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are both concentration- and timedependent. Dual parameter flow cytometry analyses validate that these nucleoside
analogues cause apoptosis. Pre-treating cells with known nucleoside transport inhibitors
reduces the cytotoxicity of Ir(III)-PPY nucleoside by blocking its cellular uptake. However,
pre-treatment with NMBPR does not block the cellular uptake of Ir(III)-BZQ nucleoside.
These results indicate that cellular entry of Ir(III)-PPY nucleoside is mediated by the
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human equilibrative nucleoside transporter one (hENT1) while transport of Ir(III)-BZQ
nucleoside occurs via a different pathway involving one or more other nucleoside
transporters. Collectively, these data provide evidence for the development of a metalcontaining nucleoside that functions as a therapeutic agent against brain cancer that uses
nucleoside transporter activity to facilitate cellular entry.

2.2

Introduction

Treatment for most brain tumors consists of a combination of three options:
surgery, radiation, and/or chemotherapy. The exact treatment regimen depends heavily on
when the malignancy is diagnosed as well as the grade of the malignancy. For example,
surgical resection is reported to be the primary form of treatment for more than 60% of
patients with stage 1 brain tumors that have low proliferation rates. However, this option
decreases to 6% in patients with stage three brain tumors that have high proliferation
rates.(114)

As a result, the combination of surgical resection and radiation therapy

has been the most significant advancement in treating GMB over the past fifty years.(115)
In general, an additive cell-killing effect is seen when both forms of treatment as combined
with chemotherapy, and this leads to better patient responses. The use of radiation therapy
as a single agent, however, has yet to be matched by any form of chemotherapy.(99)
In cases with tumors considered to be too far advanced, the goal of treatment is
palliative care that focuses primarily on relieving symptoms rather than curing the patient
of cancer. The efficacy of any individual treatment option or combinations of therapies
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depends on the patient and specific tumor characteristics. This is often the case in pediatric
and geriatric patients where surgery and ionizing radiation can potentially cause more harm
than good.(116)
The current treatment for GBM is the combined use of surgery, radiation therapy,
and the chemotherapeutic agent, temozolomide.(117)

One of the most difficult

problems associated with successfully treating primary brain tumors like GBM is the
inability of most chemotherapeutic agent to cross the blood brain barrier. In this case,
temozolomide is unique as it can pass the blood brain barrier more effectively than other
therapeutic agents such as monoclonal antibodies and small, hydrophilic molecules. While
considered the frontline chemotherapeutic agent for GBM, treatment with temozolomide
still has a very poor prognosis as most patients tend to develop resistance to this drug within
months. The mechanism for the development of resistance to temozolomide is believed to
arise from alteration in various DNA repair pathways and/or the misreplication of damaged
DNA created by temozolomide. As a cell-cycle non-specific DNA alkylating agent,
temozolomide methylates the O6 position of guanine (O6-MeG), the N7 position of guanine
(N7-MeG)

and

the

N3

position

of

adenine

(N3-MeA).(118)

Different repair pathways are activated by the lesions generated by temozolomide. For
example, correction of the N7-MeG and N3-MeG adducts is achieved via the activities of
the base excision repair (BER) pathway, methylpurine glycosylase, and AP endonuclease.
O6-MeG adducts can be directly repaired via the enzyme, O6-methylguanine DNA
methyltransferase (MGMT), or the mismatch repair pathway (MMR). Studies of GBM
cells treated with temozolomide in the presence of an overexpression of the DNA repair
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enzyme MGMT indicate that this repair process is expected to be a key factor in the
development of resistance to temozolomide.(119)
A possible alternative to treatment with temozolomide is the use of anti-metabolites
such as nucleoside analogs. Most nucleoside analogs are highly effective against different
types of cancer. For example, acute lymphocytic leukemia (ALL) and acute myeloid
leukemia (AML) are two different types of cancers that affect white blood cell components.
Nucleoside analogs such as clofarabine and fludarabine are widely used to treat these
hematological cancers.(120)

Unfortunately, the efficacy of these drugs against solid

tumor forms of cancer is not as robust. In this Chapter, I present quantitative data
examining the ability of metal-containing nucleosides to function as anti-cancer agents
against glioblastoma, an adherent cancer cell line. The goal of this thesis work is to evaluate
the ability of a novel class of metal-containing nucleoside analogs to produce a therapeutic
effect against cancers that have limited treatment options such as glioblastoma multiforme
(GBM).

2.3

Materials and Methods

Materials.
Phosphate-buffered saline (PBS), antibiotic and antifungal agents, amphotericin,
propidium iodide, PrestoBlue, DAPI, Alexa Fluor 588, and apoptosis assay kit containing
Alexa Fluor 488-labeled Annexin V used for cell-culture studies were from Invitrogen. The
human brain cancer cell line, U-87, was purchased from the American Type Culture
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Collection (ATCC). The human acute lymphoblastic cancer cell line, MOLT4, and human
fibroblasts were also purchased from ATCC.

General cell culture procedures.
All cells were cultured at 37 °C in humidified air with 5% CO2. Adherent cell lines
were maintained in Dulbecco’s modified Eagle’s medium (Mediatech, VA) with 10% fetal
bovine serum (USA Scientific), 100 g/mL penicillin (Invitrogen, NY), 100 g/mL
streptomycin and 250 L gentamycin. The doubling time was approximately 24 hours.
MOLT4 cells were maintained in Roswell Park Memorial Institute medium (RPMI-1640)
supplemented with 4.5 mg/mL L-glutamine and 10% fetal bovine serum (FBS).

Cell viability assays.
The cytotoxic effects of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside were
quantified using a standard resazurin reduction assay (PrestoBlue), opposed to the more
commonly known MTT tetrazonium assay.

Although both are colorimetric assays

commonly used to measure cell viability, the resazurin reduction assay can measure both
fluorescence and absorbance and is slightly more sensitive than tetrazonium reduction
assays that measure absorbance. They can also be incubated for shorter periods of time
than MTT assays.
Each cell was plated at a density of 20,000 cells/well in 96 well plates. Cells were
incubated for 24 hours after plating to ensure proper adhesion. Metal-containing nucleoside
was added to wells in a dose-dependent manner (1−100 M). Cells were treated with
Ir(III)-PPY nucleoside or Ir(III)-BZQ nucleoside for variable time periods (24−72 hours).
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At the desired time point, the original media was replaced with fresh media and 10 L of
PrestoBlue reagent was added (Invitrogen, NY). Conversion of the blue resazurin reagent
to the pink resorufin product by viable cells was quantified, as a result of the ability of the
inherent reducing power of the cellular cytosol. The fluorescence of each sample was
measured using a microplate reader (Ex/Em = 560/590 nm). Raw data were normalized to
100% viability (0.1% DMSO control), and EC50 values were obtained through a fit of the
data to Equation 1.

y = 100% / (1 + (EC50/[Compound]))

(1)

where [Compound] is the concentration of drug and EC50 represents the concentration of
drug required to inhibit 50% cell growth. The resulting sigmoidal/logistic curves were
plotted and derived from the KaleidaGraph Synergy Software program.

The values

calculated were also compared to those determined by other effective concentration
analysis methods (Prism) and found more accurate and acceptable.

Assessment of cell viability
Cells were treated with DMSO (vehicle) and Ir(III)-PPY nucleoside (25 or 50 µM)
or Ir(III)-BZQ nucleoside (10, 25 or 50 µM) was added in a time-dependent manner. Cells
were harvested by centrifugation and washed in phosphate-buffered saline and resuspended in 100 µL of binding buffer containing 5 µM of AnnexinV-Alexa Fluor 488
conjugate. Cells were treated with 1 µg/ mL propidium iodide (PI) and incubated at RT for
15 min followed by flow cytometry analysis. After this incubation period, an additional
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400 µL of 1X annexin-binding buffer was added. Cells were analyzed using band-pass
filters with wavelengths of 525/540 nm and 620/630 nm with a flow cytometer (Beckman
Coulter XL).
For Hoechst 33342 staining, cells were grown overnight in 12-well cell culture
dishes using an initial density of 100,000 cells/mL. Cells were then treated with variable
concentrations of metal-containing nucleoside for time periods ranging from 4 to 24 hours.
Images were obtained using an EVOSfl Advanced microscope using DAPI stain (Ex/Em
=360/447 nm) as a positive control (0.1% DMSO control) with Hoechst 33342 (5 mg/mL).
The wavelengths of the excitation and emission were 312 nm and 510 nm for the detection
of the Ir(III)-PPY nucleoside.

2.4

Results

Cell-cycle analysis using propidium iodide (PI) staining was performed by treating
cells (200,000 cells/mL) with variable concentrations of metal-containing nucleoside for
time periods varying from 24 to 48 hours. After the appropriate time period, cells were
treated with 0.25% trypsin and harvested by centrifuge at 3,000 rpm for 10 min. The
supernatant was removed and the cells were washed with 1X PBS. The cells were then
fixed with methanol and stored at −20°C overnight. Cell pellets were dislodged using 0.5
mL solution of 10 µg/mL PI and 2 mg/mL of RNAase A in saponin-based permeabilization
and wash buffer and then incubated for at 15 min prior to flow cytometry analysis.
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2.4.1

Defining the potency of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside

against the brain cancer cell line, U87

PrestoBlue® was used to quantify the effects of various anti-cancer agents
including Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on cell viability. By using the
reducing power of viable cells to quantitatively measure their proliferation, PrestoBlue®
functions similarly to other commercially available resazurin reduction assays. The
reducing environment within the cytosol of cells with an active metabolism converts
resazurin, a blue compound with no intrinsic fluorescent value, into the highly fluorescent
product, resorufin, which can be quantified by measuring a change in fluorescence. The
fluorescence values obtained in these studies were recorded at an excitation wavelength of
560 nm and emission wavelength of 590 nm. A direct correlation between fluorescence
intensity and cell viability was made to quantify the viable cells (data not show).
Initial studies evaluating the potential cytostatic and/or cytotoxic effects of MCNs
were performed by treating U87 cells with a fixed concentration of 50 µM of either
nucleoside for variable time frames (24 to 72 hours). As a negative control, cells were
treated with ~1% (v/v) of DMSO which was the solvent used to dissolve each MCN. Cells
treated solely with DMSO were then normalized to 100% cell viability to account for any
cytotoxic effect caused by the solvent.
The data provided in Figure 6 illustrate a significant difference in the percentage
of viable cells remaining after 24, 48 and 72 hour upon treatment with either MCN. In
particular, 80% of cells treated with Ir(III)-PPY nucleoside remain viable 24 hours posttreatment while only 20% of cells remain after being treated with identical concentrations
of Ir(III)-BZQ nucleoside.
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In addition, there was a time-dependency in the reduction of viable cells with each
MCN. For example, treatment with Ir(III)-BZQ nucleoside produces a large reduction in
viable cells after 48 and 72 hours of exposure. In particular, less than 10% of the cells
treated with Ir(III)-BZQ remain viable after 48 hours. Similar but less robust effects were
observed using Ir(III)-PPY nucleoside. Collectively, these data indicate that Ir(III)-BZQ
nucleoside produces a more robust effect on cell proliferation and/or cell viability
compared to Ir(III)-PPY nucleoside.
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Figure 6. Comparing the efficacy of MCNs against U87 brain cancer cells. Ir(III)BZQ nucleoside is more potent than Ir(III)-PPY nucleoside, possibly due to
structural features. All experiments were performed in triplicate.
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The difference in the pharmacological effects between Ir(III)-BZQ nucleoside and
Ir(III)-PPY nucleoside is striking, especially upon close inspection of the structures of each
MCN. While both compounds contain hydrophobic and aromatic moieties, Ir(III)-BZQ
nucleoside possesses a higher degree of aromaticity compared to Ir(III)-PPY nucleoside.
The exact reason for the increased cytotoxicity of Ir(III)-BZQ nucleoside still remains to
be determined. However, correlations between structural differences between Ir(III)-PPY
nucleoside and Ir(III)-BZQ nucleoside with their biological activities may lead to the
production of more potent MCNs. These potential mechanisms are further explored in
Chapter 4.

Ir(III)-BZQ nucleoside is more potent than Ir(III)-PPY nucleoside and Fludarabine.
To better define the potency of these MCNs, additional experiments were
performed treating U87 with variable concentrations of either MCN, ranging from 1 to 100
µM). The effects of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on these cancer
cells were evaluated at 24, 48 and 72 hour time intervals (Figure 7). Cells were treated
with DMSO and represent the negative control.
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Figure 7. Dose- and time-dependent anti-proliferative effects of Ir(III)-PPY
nucleoside and Ir(III)-BZQ nucleoside against U87 cells. Samples were compared
to fludarabine (positive control) and DMSO (negative control). DMSO is less than
1% toxic in cells. Each nucleoside concentration was varied from 1 to 100 M.
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The effective concentration (EC50) values for Ir(III)-PPY nucleoside and Ir(III)BZQ nucleoside after 24 hours were determined to be 150.1 ± 4.5 µM and 18.9 ± 4.8 µM,
respectively. After 48 hours of exposure, the potency of Ir(III)-BZQ nucleoside increases
by approximately 2.5-fold as manifest in an EC50 value of 7.6 ± 2.4 µM. A similar timedependent increase in potency was observed with Ir(III)-PPY nucleoside as well. In this
case, the EC50 value decreases ~3-fold, going from 150.1 ± 4.5 µM to 59.9 ± 4.6 µM, as
seen in Table 1. Collectively, these data validate that Ir(III)-BZQ nucleoside is
approximately 8-fold more potent than Ir(III)-PPY nucleoside. In addition, the timedependent nature for the decrease in EC50 values could reflect a kinetic phenomenon
involving active transport of each MCN into the cancer cell. This last aspect is further
explored below and in Chapter 3.
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Table 1. EC50 values for Ir(III)-PPY nucleoside, Ir(III)-BZQ nucleoside, and
fludarabine. All values reflect the mean ± standard deviation from a total of
three separate experiments.

Time

Fludarabine
(µM)

Ir(III)-PPY
(µM)

Ir(III)-BZQ
(µM)

24 hrs

>100

150.1 ± 4.5

18.9 ± 4.8

48 hrs

>100

59.9 ± 4.6

7.6 ± 2.4

72 hrs

~ 80

48.2 ± 4.5

6.9 ± 1.3
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The anti-cancer effects of these MCNs were next compared to the ant-cancer
nucleoside, fludarabine.

While this nucleoside analog is currently used to treat

hematological cancers, it is not as effective against solid tumors. Data provided in Figure
7 show the dose- and time-dependent effects of fludarabine against U87 cells. As expected,
this conventional nucleoside analog shows low potency against this adherent cell line. In
fact, an accurate EC50 value cannot be measured for fludarabine due in part to its low
potency coupled with poor solubility. However, a lower estimate of ~80 µM for fludarabine
is obtained after 72 hours of treatment. Direct comparison of the EC50 values for
fludarabine with Ir(III)-BZQ nucleoside indicates that the metal-containing nucleoside is
at least 13-fold more potent than the conventional nucleoside analog against brain cancer
cells.

2.4.2

Defining the potency of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside

against fibroblasts as a model, non-cancerous cell line.

In order for MCNs to be considered effective chemotherapeutic agents, they should
possess a wide therapeutic index and thus show high selectivity for affecting cancer cells
while not affecting non-cancerous cells. To interrogate the potential safety of these metalcontaining nucleosides, their anti-cancer effects were measured against human fibroblasts.
As before, PrestoBlue® assays were used to measure EC50 values for Ir(III)-PPY
nucleoside and Ir(III)-BZQ nucleoside against these non-cancerous cells. The effects of
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on fibroblasts were evaluated at 24, 48
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and 72 hour time intervals (Figure 8 ). Cells were treated with DMSO and represent the
negative control.
The data provided in Figure 8 directly compare the effects of Ir(III)-PPY
nucleoside and Ir(III)-BZQ nucleoside against U87 versus fibroblast cells. As indicated,
the potency of Ir(III)-PPY nucleoside is less against fibroblasts compared to U87. This is
evident by comparing the high ED50 value of 227 +/- 71 µM measured for Ir(III)-PPY
nucleoside against fibroblasts compared to the lower ED50 value of 92 +/- 25 µM measured
for Ir(III)-PPY nucleoside against brain cancer cells. Similar results are observed with
Ir(III)-BZQ nucleoside. In this case, the ED50 value for Ir(III)-BZQ nucleoside is 4-fold
higher against fibroblasts compared to U87 cells (compare ED50 values of 35 +/- 6 µM
versus 8.5 +/- 0.9 µM against fibroblasts and U87 cells, respectively). Table 2 provides a
summary of ED50 values for Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside measured
against U87 cells and fibroblasts.
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Figure 8. EC50 values for Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside measured
against U87 and fibroblasts. In each experiment, cells were treated with variable
concentrations (5, 10, 25, 50, and 100 µM) of each nucleoside analog for 48 hours.
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Table 2. The anti-proliferative effects of Ir(III)-PPY and Ir(III)-BZQ are timedependent. Confirms that Ir(III)-BZQ is ~7-fold more potent than Ir(III)-PPY Ir(III)PPY and Ir(III)-BZQ show a ~3-fold selectivity for U87 cells compared to fibroblasts
Ir(III)-BZQ

Ir(III)-PPY
U87

Fibroblasts

U87

Fibroblasts

Dt = 24 hours

106 +/- 21 M

315 +/- 85 M

26 +/- 6 M

73 +/- 20 M

Dt = 48 hours

47 +/- 7 M

220 +/- 65 M

9.3 +/- 1.5 M

34 +/- 8.5 M
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In general, these data indicate that both metal containing nucleosides display more
potent anti-proliferative effects against U87 cells compared to fibroblast. This result
suggests that both compounds have a potentially acceptable therapeutic index. However,
additional cell-based and animal studies are needed to fully explore the potential safety and
utility of either Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside as anti-cancer agents
targeting brain cancer.

2.4.3

Comparing the efficacy and selectivity of Ir(III)-PPY nucleoside and Ir(III)-

BZQ nucleoside versus conventional anti-cancer agents against brain cancer

Currently, the most effective drug used to treat GBM is temozolomide (TMZ), also
known by the brand names Temodar, Temodal, and Temcad. This agent induces cell death
by damaging DNA, specifically causing the formation of O6-methylguanine, N7methylguanine, and N3-methyladenine DNA adducts. Unfortunately, resistance to
temozolomide develops in patients as a result of increased levels of the DNA repair
enzyme,

O6-methylguanine

DNA

methyltransferase

(MGMT).(121)

Dose-limiting hematologic toxicity also remains an issue with temozolomide treatment,
and has resulted in the study of numerous regiments to increase the therapeutic effects of
temozolomide.
To evaluate the efficacy and selectivity of temozolomide against brain cancer, the
anti-cancer effects of this compound were measured against U87 cells and fibroblasts as
previously described using the PrestoBlue® assay to measure cell viability. Data provided
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in Figure 9 compares the effects of temozolomide against U87 cells and fibroblasts at 48
hours post-treatment. It is clear that temozolomide affects both cancerous and noncancerous cells equally well. As such, this particular anti-cancer agent shows a low
therapeutic index. By inference, Ir(III)-BZQ nucleoside represents a potentially more
effective therapeutic agent against brain cancer for two (2) reasons. First, the metal
containing nucleoside has a wider therapeutic index compared to temozolomide (~4 versus
1). Secondly, the potency of Ir(III)-BZQ nucleoside is significantly lower than
temozolomide against brain cancer cells (compare ED50 values of 8.5 +/- 0.9 µM versus
>100 µM for Ir(III)-BZQ nucleoside and temozolomide, respectively).
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Figure 9. Temozolomide displays low potency against glioblastoma (U87) cells and
non-cancerous fibroblasts. In addition, temozolomide is non-selective as it affects
both cell types equally.
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Previously, I demonstrated that the nucleoside analog, fludarabine, was 13-fold less
potent than Ir(III)-BZQ nucleoside against U87 cells (Figure 7). The low potency of this
conventional nucleoside analog prompted testing against a hematological cell line to verify
that the nucleoside analog does exert anti-cancer effects against hyperproliferative cells. In
these experiments, I used the nucleoside analog, clofarabine, which is structurally similar
to fludarabine. Experiments were performed measuring the potency of clofarabine against
the acute lymphoblastic cell line, MOLT4, as well as the glioblastoma cell line, U87.
MOLT4 cells were treated with variable concentrations of clofarabine (0.01 – 100 µM) for
48 hours. After this time period, cell viability was measured via microscopy techniques
using trypan blue staining to differentiate viable from non-viable cells. The ratio of viable
cells to total cell cells (viable and non-viable) was used to calculate the % viable cells as a
function of nucleoside concentration, and this value was used as an indication of the
cytotoxic effects of the nucleoside analog. Results provided in Figure 10 show that
clofarabine produces a robust cytotoxic effect against MOLT4 cells. A plot of % viable
cells as a function of clofarabine concentration yields a sigmoidal dose-response curve
from which an LD50 value of 220 +/- 20 nM is obtained through a fit of the data to Equation
(1).
Similar experiments testing the efficacy of clofarabine against U87 yield
significantly different results. In this case, treating U87 cells with the conventional
nucleoside analog produces a minimal effect on cell viability as there is only a ~15%
reduction in cell viability at the highest concentration of clofarabine tested (100 µM).
Collectively, these results demonstrate that clofarabine is a highly effective anti-cancer
against hematological malignancies such as acute lymphoblastic leukemia as illustrated by
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its high potency. However, it is not effective against adherent cancer cells such as brain
cancer cells. Again, the implication of this result is that Ir(III)-BZQ nucleoside is a more
efficacious nucleoside analog compared to fludarabine and clofarabine as a result of its
higher potency.
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Figure 10. Clofarabine displays high potency against acute lymphoblastic leukemia
cells (MOLT4) but not against glioblastoma (U87) cells.
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An additional experiment was performed to interrogate the selectivity of
clofarabine against cancerous versus non-cancerous cells. In this experiment, the anticancer effects of clofarabine were measured against U87 cells and fibroblasts as previously
described using the PrestoBlue® assay to measure cell viability. Results provided in
Figure 11 indicate that clofarabine effects both cancerous (U87) and non-cancerous
(fibroblast) cells equally. Again, this lack of selectivity indicates that clofarabine possess
a low therapeutic index against adherent cells.
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Figure 11. Clofarabine shows low potency against both U87 cells and noncancerous fibroblasts. Both cell lines are affected equally by clofarabine,
consistent with a lack of selectivity of this anti-metabolite against adherent
cancer cells.
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Determining the mechanism of cell death induced by metal containing nucleosides.
The cellular mechanism by which Ir(III)-PPY nucleoside and Ir(III)-PPY
nucleoside causes cell death in u87 cells was evaluated employing dual parameter FACS
analyses to measure propidium iodide (PI) uptake coupled with Alexa Fluor 488 Annexin
V conjugate staining. In this analysis, live cells (negative for either fluorophore) are easily
distinguished from cells that are early apoptotic (annexin V positive and PI negative), late
apoptotic (PI and annexin V positive), or necrotic (PI positive and annexin V negative).
Results provided in Figure 12 show that treatment with 10 and 25 µM Ir(III)-PPY
nucleoside, respectively, causes significant increases in early and late stage apoptosis
compared to cells treated with DMSO. This result is consistent with experiments measuring
cellular viability described earlier in which there was a dose-dependent decrease in cell
viability.
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Figure 12. Dual parameter flow cytometry analysis of U87 cells treated with Ir(III)PPY nucleoside (10 and 25 uM) and Ir(III)-BZQ nucleoside (10, 25 and 50 uM) for
48 hours. Analysis reveals again confirms that Ir(III)-BZQ nucleoside is more
effective than Ir(III)-PPY nucleoside as it induces a more robust apoptotic effect in
U87 cells.
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Similar experiments were performed testing the ability of Ir(III)-BZQ nucleoside
to induce apoptosis. Results provided in Figure 12 again show that treatment with 10, 25,
and 50 uM Ir(III)-BZQ nucleoside leads to significant increases in both early and late stage
apoptosis. These results again recapitulate earlier results demonstrating that Ir(III)-BZQ
nucleoside reduces cell viability in a dose-dependent manner.
Table 3 summarizes the results of dual parameter flow cytometry analyses of
treating U87 cells with Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside. These data
provide three (3) important results. First, the anti-cancer effects of both metal-containing
nucleosides against U87 cells reflect apoptotic cell death rather than through a simple antiproliferative effect or by cell death caused by necrotic mechanism. This distinction is
important since apoptotic cell death is preferred over necrotic cell death as the latter can
cause inflammation, septic shock, and/or edema.(122, 123)

Each response

can compromise a patient’s response to chemotherapy. Secondly, these data again
demonstrate a dose-dependent effect on apoptosis. Finally, these results recapitulate earlier
data demonstrating that Ir(III)-BZQ nucleoside is more potent than Ir(III)-PPY nucleoside.
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Table 3. Summary of dual parameter flow cytometry analysis of Ir(III)-PPY nucleoside
and Ir(III)-BZQ nucleoside against U87 cells.

Condition

Viable

Early
Apoptotic

Late
Apoptotic

Necrotic

DMSO

92.0%

1.9%

2.4%

3.7%

50 µM Ir(III)-PPY
nucleoside

87.3%

5.6%

4.5%

3.1%

50 µM Ir(III)-BZQ
nucleoside

65.7%

8.1%

13.8%

12.4%
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To further evaluate the underlying mechanism for the induction of apoptosis, flow
cytometry using propidium iodide staining to measure cell-cycle progression in U87 cells
treated with DMSO, 50 µM Ir(III)-PPY nucleoside or 50 µM Ir(III)-BZQ nucleoside was
performed. The results of these experiments are provided in Figure 13. Untreated U87
cells show a normal cell-cycle distribution for asynchronous diploid cells. In this case, most
cells exist at G1 (74.6 +/- 3.3%) while smaller population of cells exist at S-phase (7.8 +/1.3%), G2/M (13.5 +/- 2.2%), and sub-G1 (4.1 +/- 1.3%). The sub-G1 population
represents cells that are undergoing nuclear fragmentation, a hallmark of apoptotic cell
death. Cells treated with 50 uM Ir(III)-PPY nucleoside show significant perturbations in
cell-cycle progression compared to cells treated with DMSO. In this case, there is a
reduction in the population of cells that exist at G1 (51.6 +/- 2.5%) with concomitant
increases in the population of cells at S-phase (16.4 +/- 3.3%), G2/M (20.8 +/- 1.8%), and
sub-G1 (11.2 +/- 2.3%). These results provide clear evidence that the Ir(III)-PPY
nucleoside induces apoptosis as manifest by the increase in sub-G1. In addition, there are
significant increases in the percentages of cell populations at S-phase and G2/M.
At face value, these results suggest that Ir(III)-PPY nucleoside can affect cell-cycle
progression in diploid cells. Indeed, similar results were observed in KB3-1 cells treated
with Ir(III)-PPY nucleoside (Choi, J-S., Gray, T. and Berdis, A. J. Submitted to
Theranostic). In this cell line, the effect on cell cycle progression was more dramatic. In
fact, the effects of Ir(III)-PPY nucleoside on cell-cycle distribution in KB3-1 cells could
not be accurately determined using a standard diploid cell model. Instead, values were
calculated using a diploid-tetraploid model in which there is a heterogeneous population of
cells containing two and four sets of chromosomes, respectively. Using this model, the
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diploid population of cells have significant alterations in cell-cycle progression as indicated
by a decrease in cells at G1 (19.9 +/- 7.1%) coupled with increased cell populations at Sphase (43.2 +/- 7.8%) and G2/M (36.9 +/- 2.9%). Tetraploid cells also showed
perturbations in cell-cycle progression in which there was a decrease at G1 (34.2 +/- 1.0%)
and S-phase (20.5 +/- 6.6%) coupled with an increase at G2/M (45.3 +/- 5.7%). Taken
together, these results indicate that Ir(III)-PPY nucleoside affects cell-cycle progression in
both cervical cancer cells (KB3-1) and brain cancer cells (U87). However, it is intriguing
that Ir(III)-PPY nucleoside has a more pronounced effect towards inducing apoptosis in
U87 cells compared to KB3-1 cells. The underlying cellular mechanism for this difference
is unknown at this time. One possibility could reflect simple differences in cell type, i.e.,
epithelial versus glial cell. Another possibility is differences in either cell line in the
expression levels of key proteins involved in cell-cycle progression such as p53.
Cells treated with 50 µM Ir(III)-BZQ nucleoside also show significant
perturbations in cell-cycle progression compared to cells treated with DMSO. In this case,
the reduction in the population of cells at G1 (40.0 +/- 8.5%) coincides with a significant
increase in the sub-G1 population of cells (45.5 +/- 9.3%). This increase in sub-G1 provides
clear evidence that Ir(III)-BZQ nucleoside induces apoptosis. Again, the apoptotic effect
induced by Ir(III)-BZQ nucleoside is substantially greater than that produced by treatment
with Ir(III)-PPY nucleoside. These data are consistent with the results described above
using dual parameter flow cytometry to interrogate the mechanism of cell death. It is also
interesting to note that Ir(III)-BZQ nucleoside does not appear to affect cell cycle
progression as does Ir(III)-PPY nucleoside. This statement is based on the fact that the
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population of cells at S-phase (8.3 +/- 1.5%) and G2/M (6.2 +/- 2.2%) are similar to values
obtained to cells treated with DMSO.
Collectively, these data indicate that both Ir(III)-PPY nucleoside and Ir(III)-BZQ
nucleoside cause cell death via an apoptotic pathway as opposed to necrosis. However, it
is striking that Ir(III)-PPY nucleoside appears to affect cell-cycle progression in U87
whereas Ir(III)-BZQ nucleoside has a minimal effect, if any, on cell cycle progression.
Further studies will be needed to first confirm this result and then probe the underlying
mechanism for this difference.
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DMSO (Dt = 48 hours)

50 M Ir(III)-PPY nucleoside (Dt = 48 hours)

50 M Ir(III)-BZQ nucleoside (Dt = 48 hours)

Figure 13. Flow cytometry analysis of U87 cells treated with Ir(III)-PPY nucleoside 50
µM) and Ir(III)-BZQ nucleoside (50 µM) for 48 hours. The higher levels of sub-G1
DNA in Ir(III)-BZQ nucleoside treated cells indicates that it induces a more robust
apoptotic effect than Ir(III)-PPY nucleoside in U87 cells.
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Investigating the nucleoside transporter(s) involved in the uptake of Ir(III)-BZQ
Nucleoside.
There are two distinct families of nucleoside transporters that include equilibrative
nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs). In
humans, there are four ENT isoforms (designated hENT1 through hENT4) that display
broad transport activities for both pyrimidine and purine (deoxy)nucleosides, as discussed
previously.

Each hENT isoform catalyzes the bidirectional transport of nucleosides

following a concentration gradient. hCNTs consist of three isoforms (hCNT1-3) and
catalyze the transport of (deoxy)nucleosides against a gradient by coupling nucleoside
movement with sodium or proton co-transport.(78-81)

hCNT1 and hCNT2

translocate pyrimidine and purine (deoxy)nucleoside, respectively, by a sodium-dependent
mechanism whereas CNT3 shows broad substrate selectively and possesses the unique
ability to translocate nucleosides in both sodium- and proton-coupled manners.(124)
The goal here is to determine which nucleoside transporter is involved in the uptake
of Ir(III)-BZQ nucleoside in U87 cells. Previous studies in the Berdis lab performed by Dr.
Jung-Suk Choi demonstrated that Ir-PPY nucleoside is transported into KB3-1 cells
primarily by the activity of hENT1 (Choi, J-S., Gray, T. and Berdis, A. J. Submitted to
Theranostic). This was determined by demonstrating that cells pre-treated with the 10 µM
S-(4-nitrobenzyl)-6-thioinosine (NMBPR), a specific inhibitor of hENT1, blocked the
uptake of Ir(III)-PPY nucleoside by ~90% compared to cells pre-treated with DMSO.
In this study, I used a similar approach to evaluate if hENT1 participates in the
uptake of Ir(III)-BZQ nucleoside. In these experiments, U87 cells were pre-treated with
either DMSO (control) or 10 µM NMBPR for 24 hours. After this time, the media was
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removed and replaced with media containing variable concentrations of Ir(III)-BZQ
nucleoside in the absence and presence of 10 µM NMBPR. Cells were analyzed after 48
hours using PrestoBlue dye to measure cell viability. The results of these experiments are
provided in Figure 14.
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Figure 14. hENT1 does not participate in the cellular transport of Ir(III)-BZQ
nucleoside. Pre-treatment of U87 cells with 10 M NMPBR has no effect on the anticancer effects of Ir(III)-BZQ nucleoside.
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Table 4. A summary of the Ir(III)-BZQ effective concentration (EC50) values
measured in the absence ad presence of the hENT1 specific inhibitor NMBPR at
10 M.
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Representative data provided in Figure 14 shows that the inclusion of the hENT1
inhibitor has essentially no effect on reducing the anti-cancer effects of Ir(III)-BZQ
nucleoside against U87 cells. This analysis was performed twice, and the collective results
are summarized in Table 4. As indicated, the ED50 values for Ir(III)-BZQ nucleoside are
not altered significant by the presence of NMBPR, and indicate that hENT1 does not likely
participate in the transport of this metal-containing nucleoside. By interference, it is likely
that another nucleoside transporter, either equilibrative or concentrative, is involved in the
uptake of Ir(III)-BZQ-nucleoside. Alternatively, the metal-containing nucleoside may gain
cellular access by simple passive diffusion. These potential mechanisms are explored
further in Chapter 3 using the unique spectroscopic properties of these metal-containing
nucleosides to visualize their cellular uptake.
However, additional experiments were performed to further define the nucleoside
transporter responsible for the uptake of Ir(III)-PPY nucleoside. In these experiments, U87
cells were pre-treated with either DMSO (control) or 10 µM NMBPR for 24 hours. After
this time, the media was removed and replaced with media containing variable
concentrations of Ir(III)-PPY nucleoside in the absence and presence of 10 µM NMBPR.
Cells were analyzed after 48 hours using PrestoBlue dye to measure cell viability. The
results of these experiments, provided in Figure 15, illustrate that co-treating cells with 10
µM NBMPR and metal-containing nucleoside generates higher levels of viable cells
compared to cells treated with Ir(III)-PPY nucleoside alone. More precisely, pre-treatment
of U87 cells with 10 µM NMPBR causes a “right-shift” in the dose response curve for
Ir(III)-PPY nucleoside, indicating that the potency of Ir(III)-PPY nucleoside is lowered by
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the hENT1 inhibitor. At the molecular level, the chemoprotective by NMBPR occurs by
inhibiting hENT1 which then blocks the cellular transport of Ir(III)-PPY nucleoside.
These results are consistent with data showing that NBMPR treatment can produce
a chemoprotective effective against Ir(III)-PPY nucleoside in KB3-1 cells. Collectively,
these data support a mechanism in which Ir(III)-PPY nucleoside enters cells via an active
transport mechanism catalyzed by hENT1. Surprisingly, the structurally related analog,
Ir(III)-BZQ nucleoside, does not appear to be transported by hENT1 and therefore
undergoes active transport by another nucleoside transporter or via passive diffusion.
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Figure 15. hENT1 participates in the cellular transport of Ir(III)-PPY nucleoside.
Pre-treatment of U87 cells with 10 M NMPBR causes a “right-shift” in the dose
response curve for Ir(III)-PPY nucleoside, indicating that the hENT1 inhibitor
lowers the potency of Ir(III)-PPY nucleoside by presumably blocking its cellular
entry.
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2.5 Discussion

In this Chapter, I demonstrate that Ir(III)-PPY nucleoside and Ir(III)-BZQ
nucleoside are novel metal-containing nucleosides that produce anti-cancer effects against
the glioblastoma cell line, U87. Despite being structurally similar, the metal-containing
nucleosides display unique features that highlight how subtle permutations in structure can
produce different pharmacodynamic effects, This is evident as the potency of Ir(III)-BZQ
nucleoside is ~8-fold lower than Ir(III)-PPY nucleoside. This difference in potency reflects
the ability of Ir(III)-BZQ nucleoside to induce apoptosis at lower concentrations. In this
case, dual parameter FACS analyses measuring propidium iodide (PI) uptake and Alexa
Fluor 488 Annexin V conjugate staining was used to demonstrate that

Ir(III)-PPY

nucleoside and Ir(III)-BZQ nucleoside induce apoptosis rather than necrosis. These
apoptotic effects are both dose- and time-dependent, and this result is consistent with
previous results measuring cellular viability (vide supra). However, perhaps the most
striking difference is the fact Ir(III)-PPY nucleoside is transported by hENT1 while Ir(III)BZQ, the more potent analog, does not appear to an effective substrate for hENT1.
These differences raise several intriguing questions regarding the higher potency of
Ir(III)-BZQ nucleoside compared to Ir(III)-PPY nucleoside. One possibility could reflect
different transport mechanism in which Ir(III)-BZQ nucleoside accumulates in cancer cells
more rapidly than Ir(III)-PPY nucleoside. This particular question is addressed more
thoroughly in Chapter 3 in which I use the spectroscopic properties of these metalcontaining nucleosides to measure their cellular import as well as evaluate their cellular
distribution. Both pieces of information can provide unique information that can explain
potential differences in potency. However, in this chapter, I focus on attempting to explain
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the molecular mechanism by which these metal-containing nucleosides induce apoptosis.
I begin this by first reviewing what is known regarding the biochemical mechanisms of
action for conventional nucleoside analogs such as fludarabine and clofarabine. The
primary cytotoxic mechanism for most nucleoside analogs is incorporation of their
corresponding nucleoside triphosphates into DNA, causing chain termination of DNA
synthesis and the activation of apoptosis. For example, the mechanism for the incorporation
of the triphosphate form of fludarabine (F-ara-ATP) by various human DNA polymerases
has been extensively studied.(16, 28, 29, 125, 126)

Replicative polymerases such as

pol , pol , pol , and pol incorporate F-ara-ATP after which DNA synthesis is
inhibited.(35, 127)

One incorporated into DNA, F-ara-AMP is a poor substrate

for subsequent DNA elongation, making it an unusually effective chain terminator.
Although it is a formal possibility that these metal-containing nucleoside acting as chain
terminators, the data collected thus far is not consistent with this mechanism. Specifically,
inhibiting cellular DNA synthesis by using chain terminating nucleosides usually induces
cell-cycle arrest at S-phase. The flow cytometry data presented here (Figure 16) with
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside does not show evidence for cell-cycle
arrest at S-phase.
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Figure 16. (A) KB3-1 cells treated with Ir(III)-PPY nucleoside undergo apoptosis
rather than necrosis. (B) The apoptotic effects of Ir(III)-PPY nucleoside reflect
alterations in cell-cycle progression.
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However, nucleoside analogs can also produce indirect effects on nucleic acid metabolism
that can cause cell death. The predominant effect is by depleting cellular nucleotide pools
via the inhibition of ribonucleotide reductase and various nucleoside kinases involved in
converting natural nucleoside to their corresponding mono-, di-, and triphosphate
metabolites.(98)

Since DNA replication requires high levels of cellular dNTPs, the

depletion of nucleotide pools can delay cellular DNA synthesis. While not specifically
examined here, this mechanism is also not consistent with the flow cytometry data. As
indicated above, inhibiting cellular DNA synthesis by depleting nucleotide pools would
also likely induce cell-cycle arrest at S-phase. The flow cytometry data presented here with
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside does not show evidence for cell-cycle
arrest at S-phase.
Another important cytotoxic effect of purine nucleoside analogs, independent of
directly inhibiting DNA synthesis, is via the induction of apoptosis by caspase activation.
One classic feature of apoptosis is internucleosomal cleavage of genomic DNA that occurs
after caspase activation. Caspase-3 is particularly important as it can be activated in the
cytosol by dATP and cytochrome c.(6, 128)

Since purine nucleoside analogs

such as F-ara-ATP mimic dATP, they may function as surrogates to activate dATPdependent caspases and initiate apoptosis. Indeed, treatment with F-ara-ATP causes the
induction of apoptosis both in cell culture systems and in primary chronic lymphocytic
leukemia (CLL) cells.(36, 129, 130)
Another possibility is that these metal-containing nucleosides inhibit ATPdependent kinases to produce an apoptotic effect. Indeed, the Berdis lab demonstrated that
gold-containing indoles induced cell death in a time and dose dependent manner by
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inhibiting various protein kinases. Current work is underway to examine the ability of
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside to act as kinase inhibitors.
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CHAPTER III
CELL-BASED STUDIES EVALUATING THE POTENTIAL OF METALCONTAINING NUCLEOSIDES TO FUNCTION AS NON-INVASIVE
BIOPHOTONIC IMAGING AGENTS

3.1

Abstract

In Chapter 2 of this thesis, I demonstrated that the metal-containing nucleosides
designated Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside produce anti-cancer activity
against brain cancer cell lines. Despite being structurally similar, these nucleoside analogs
displayed striking differences with respect to potency and dependency of nucleoside
transporters for cellular uptake. In this chapter, I use the unique spectroscopic properties
of these metal-containing nucleosides to further elucidate their mechanism of action.
Microscopy studies measuring fluorescence associated with these analogs demonstrate that
both Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are taken up into U87 cells in a
time- and dose-dependent manner. In this respect, the cellular uptake of Ir(III)-BZQ
nucleoside is more efficient than that of Ir(III)-PPY nucleoside, and this difference
correlates with measured differences in their potency. Additional microscopy studies
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demonstrate that pre-treatment with NBMPR, an inhibitor of hENT1, blocks the uptake of
Ir(III)-PPY nucleoside but has no appreciable effect on the uptake of Ir(III)-BZQ
nucleoside. These observations confirm the results of chemoprotective studies using
NBMPR to block the cytotoxic effects of Ir(III)-PPY nucleoside but not that of Ir(III)-BZQ
nucleoside. Collectively, these results demonstrate that Ir(III)-PPY nucleoside is a
substrate for hENT1 whereas the related nucleoside, Ir(III)-BZQ nucleoside, is not.
Finally, high-field microscopy studies were performed to define the intracellular
localization of these metal-containing nucleosides in brain cancer cells. Preliminary data is
provided indicating that both metal-containing nucleoside show complex patterns of
localization that are both time- and concentration- dependent. However, microscopy
evidence is provided indicating that both nucleoside analogs initially accumulate in the
cytoplasm. In addition, Ir(III)-PPY nucleoside shows distinct accumulation patterns in the
nucleus whereas the localization of Ir(III)-BZQ nucleoside appears to be primarily in the
mitochondria. Results of these studies are discussed within the context of pharmacological
studies previously described in Chapter 2.

3.2

Introduction

Understanding the hyperproliferative nature of cancer cells is critical to improving
current treatments. As cancer cells replicate abnormally fast, the efficient uptake and
subsequent metabolism of nucleosides is essential for these pathogenic cell to support
increased metabolism, DNA and RNA synthesis, and cell division. Essential to this
increased metabolism is the composite activity of various nucleoside transporters.
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Concentrative nucleoside transporters (CNT) and equilibrative nucleoside transporters
(ENT) represent the two classes of membrane proteins responsible for the influx of natural
nucleosides into almost all types of cells.
Most contemporary approaches to quantify the cellular uptake of nucleoside
employ isotopically-labeled nucleosides as surrogates. The reliance on this approach
unfortunately produces several logistical problems such as special requirements for
synthesis and the use of discontinuous time-based assays to monitor nucleoside influx
and/or efflux. In addition, the use of radiolabeled nucleosides has obvious limitations
toward measuring nucleoside transport and tissue distribution in animals. To overcome
these deficiencies, the Berdis lab recently developed a metal-containing nucleoside analog
designated Ir(III)-PPY nucleoside, which contains iridium embedded within a biscyclometalated scaffold attached to a deoxyriboside. Cyclometalated complexes of
iridium(III) were chosen as rugged, cell-compatible emitters. In addition, these complexes
are high-yielding phosphorescent luminophores that undergo rational tuning to emit visible
light across a range of wavelengths.(102, 131-135)
As described earlier, there are two distinct families of nucleoside transporters that
include equilibrative nucleoside transporters (ENTs) and concentrative nucleoside
transporters (CNTs). Humans possess four ENT isoforms, designated hENT1-4, that
display broad transport activities for pyrimidine and purine deoxy(nucleosides).(136, 137)
Each hENT isoform catalyzes the bidirectional transport of nucleosides following a
concentration gradient. There are three hCNT isoforms (hCNT1-3) that catalyze the
transport of (deoxy)nucleosides against a gradient by coupling nucleoside movement with
sodium or proton co-transport.(138, 139)

hCNT1 and hCNT2 translocate
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pyrimidine and purine (deoxy)nucleoside, respectively, by a sodium-dependent
mechanism. hCNT3 is unique in that it translocates nucleosides by sodium- and protoncoupled mechanisms. This brief overviews highlights the complexity of nucleoside
transport, especially in pathogenic states such as cancer. The identification of specific
nucleoside transporters that are overexpression and/or up-regulated is essential to better
define pharmacological effects of conventional nucleoside analogs. As such, a goal of this
chapter is to use metal-containing nucleoside as surrogates to gain a better understanding
of the fundamental process of nucleoside transport. This information can then be
extrapolated to further understanding the physiological processes involving drugs that
induce cytotoxic effects against hyperproliferative diseases such as cancer. The typical
clinical method to measure a drug within the body are based on correlations between the
levels of the drug in serum and other tissues as a function of time. As a result, it is very
difficult to determine the minimum concentration of a chemotherapeutic agent that is
necessary to produce the desired therapeutic effect without the harmful side effects
associated with excess concentrations of drug. With high emission yields and favorable
luminescence lifetimes, the phosphorescent metal-containing nucleosides described here
may serve as improved diagnostic tools for alternatives to currently used radiolabeled
nuclides with the potential to replace the use of harmful radioactive materials.
An additional advantage of these unique analogs is their capability to demarcate
their location inside the cell. Thus, a clear innovation of this study is to use these metalcontaining nucleoside analogs as novel chemical probes to reveal how nucleoside analogs
accumulate into various cellular organelles. In this case, the ability to define their cellular
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location can provide augmenting support for their function as anti-cancer agents as well as
aid to identify potential cellular targets associated with their pharmacological effects.

3.3

Materials and Methods

Materials.
Phosphate-buffered saline (PBS), antibiotic and antifungal agents, amphotericin,
propidium iodide, PrestoBlue, DAPI, Alexa Fluor 588, and apoptosis assay kit containing
Alexa Fluor 488-labeled Annexin V used for cell-culture studies were from Invitrogen. The
human brain cancer cell line, U-87, was purchased from the American Type Culture
Collection (ATCC).

General cell culture procedures.
All cells were cultured at 37 °C in humidified air with 5% CO2. Adherent cell lines
were maintained in Dulbecco’s modified Eagle’s medium (Mediatech, VA) with 10% fetal
bovine serum (USA Scientific), 100 µg/mL penicillin (Invitrogen, NY), 100 µg/mL
streptomycin and 250 µL gentamycin. The doubling time was approximately 24 hours.
MOLT4 cells were maintained in Roswell Park Memorial Institute medium (RPMI-1640)
supplemented with 4.5mg/mL L-glutamine and 10% fetal bovine serum (FBS).
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Microscopy studies to evaluate the cellular uptake of Ir(III)-PPY nucleoside and Ir(III)BZQ nucleoside.
The uptake of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside into U87 cells was
visualized by microscope imaging. Cells were plated on 35 mm dish glass bottom
microwell dishes and pre-incubated in the absence or presence of adenosine (200 µM) or
NBMPR (10 µM). After 24 hours, cells were co-cultivated with Ir(III)-PPY nucleoside or
Ir(III)-PPY nucleoside for time periods varying from 1 to 2 days. Cells were washed twice
with PBS, and exposed to fresh medium in the presence of 1 mg/mL DAPI, Alexa Fluor
568 phalloidin (1:2000), and/or 10 nM MitoPT-TMRE for up to 15 min. After this time,
cells were washed twice with 1X PBS, fixed with 4% paraformaldehyde, and washed twice
more with 1X PBS. Images were obtained using an EVOSfl Advanced microscope using
DAPI stain (Ex/Em =360/447 nm) as a positive control (0.1% DMSO control) with
Hoechst 33342 (5 mg/mL). The wavelengths of the excitation and emission were 312 nm
and 510 nm for the detection of the Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside.
Quantification of Ir(III)-PPY nucleoside uptake into KB3-1 cells was performed as
previously described. Briefly, cells were plated overnight onto 12 well plates at a density
of 200,000 cells per well. The cells were then pre-incubated with DMSO or NBMPR for
24 hours prior to treatment with variable concentrations of Ir(III)-PPY nucleoside for time
intervals of 1 or 2 days. Cells were treated with 0.25% trypsin and harvested by
centrifugation. The supernatant was removed and then washed twice with 1X PBS. Cells
were lysed with 0.1% triton X-100 in 1X PBS, and then observed by fluorescent plate
reader (Ex 340/Em 480).
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3.4

Results

Microscope imaging of cells treated with Ir(III)-BZQ nucleoside.
Previous work in the Berdis lab demonstrated the uptake of Ir(III)-PPY nucleoside
into KB3-1 cells occurs in a dose- and time-dependent manner. The studies described here
use similar techniques employing fluorescence microscopy to evaluate the uptake of Ir(III)BZQ nucleoside into U87 cells. In these initial studies, cells were treated with 10 or 50 µM
of Ir(III)-BZQ nucleoside. At variable time intervals (4-48 hours), cells were washed with
PBS to remove metal-containing nucleoside, and images of treated cells were taken at using
an excitation wavelength of 340 nm and an emission wavelength of 480 nm.
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Figure 17. Fluorescence microscopy images demonstrate the accumulation of
Ir(III)-BZQ nucleoside into U87 cells in a dose and time dependent manner.
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Figure 17 provides images of cells treated with Ir(III)-BZQ nucleoside at variable times.
These images provide clear evidence for an increase in fluorescence signal that reflects
intracellular accumulation of the metal-containing nucleoside in U87 cells. This
accumulation occurs in a time-dependent manner, and maximal accumulation of Ir(III)BZQ nucleoside occurs rather rapidly (within 8 hours post-treatment). It should also be
noted that these initial data indicate a dose-dependent effect on nucleoside uptake as judged
by the higher fluorescence intensity detected using 50 µM Ir(III)-BZQ nucleoside
compared to 10 µM Ir(III)-BZQ nucleoside.

Correlating the uptake of Ir(III)-BZQ nucleoside with its pharmacological effects.
The dose-dependency of the uptake of Ir(III)-BZQ nucleoside was similarly
evaluated. In these experiments, U87 cells were treated with variable concentrations of
Ir(III)-BZQ nucleoside for a fixed time interval (48 hours) and then analyzed via
fluorescence microscopy to detect nucleoside uptake. Data provided in Figure 18 shows
that U87 cells treated with a low concentration of Ir(III)-BZQ nucleoside (5 µM) have few
cells displaying a fluorescent signal. Since the emission intensity reflects intracellular
accumulation of Ir(III)-BZQ nucleoside, a low signal is consistent with low cellular uptake.
As the concentration of Ir(III)-BZQ nucleoside is increased, there is a concomitant increase
in fluorescence signal that represents a greater number of cells that have imported Ir(III)BZQ nucleoside. Collectively, these microscopy data demonstrate a dose-dependency in
the accumulation of Ir(III)-BZQ nucleoside. Taken together with the pharmacological
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studies descried in Chapter 2, there is a qualitative correlation between the anti-cancer
effect of Ir(III)-BZQ nucleoside with its cellular accumulation.
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DMSO

5 M BZQ

10 M BZQ

25 M BZQ

50 M BZQ

Figure 18. U87 cells treated with a low concentration of Ir(III)-BZQ nucleoside have
fewer cells displaying a fluorescent signal.
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Similar experiments were performed measuring the dose-dependency of the uptake
of Ir(III)-PPY nucleoside. Data in Figure 19 show that U87 cells treated with a low
concentration of Ir(III)-PPY nucleoside have fewer cells displaying a fluorescent signal.
As before, the emission intensity reflects intracellular accumulation of Ir(III)-PPY
nucleoside. Thus, a low fluorescence signal reflects low cellular uptake. Similar to
experiments performed using Ir(III)-BZQ nucleoside, there is an increase in fluorescent
signal as the concentration of of Ir(III)-PPY nucleoside is increased. These microscopy
data also demonstrate a correlation between the anti-cancer effects of Ir(III)-PPY
nucleoside with its cellular uptake. However, an important distinction is that these
microscopy data highlight that the uptake of Ir(III)-PPY nucleoside is far less efficient
compared to that for Ir(III)-BZQ nucleoside.
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DMSO

DMSO

10 M PPY

10 M BZQ

50 M PPY

50 M BZQ

Figure 19. U87 cells treated with variable concentrations of MCN nucleoside analogs
after 48 hrs correspond to the dose-response curves previously determined.
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hENT1 facilitates the transport of Ir(III)-PPY nucleoside but not Ir(III)-BZQ nucleoside.
To further interrogate the involvement of hENT family members in the transport of
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside, I next examined the ability of the hENT
inhibitor, NBMPR, to block the fluorescence signals associated with the uptake of either
metal-containing nucleoside. In these experiments, U87 cells were first pre-treated with
DMSO or 10 µM NBMPR for 24 hours and then treated with fixed concentrations of Ir(III)PPY nucleoside (25 µM) or Ir(III)-BZQ nucleoside (10 µM) for another 48 hours. After
this time period, cells were washed with PBS and then analyzed via fluorescence
microscopy to detect nucleoside uptake. Cells were also stained with DAPI (1 ng/mL) to
identify the nuclei of cells.
Microscope images (10X magnification) provided in Figure 20 demonstrate that
U87 cells treated with 25 µM Ir(III)-PPY nucleoside and 10 µM NBMPR have
significantly lower fluorescence intensities compared to cells treated with 25 µM Ir(III)PPY nucleoside in the absence of NBMPR. This result indicates that Ir(III)-PPY nucleoside
enters cells via active transport catalyzed by hENT1. This result confirms pharmacological
data provided in Chapter 2 that demonstrated the chemopreventive effects of NBMPR
against Ir(III)-PPY nucleoside.
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25 M PPY (Dt = 2 days)

10 M NMBPR -> 25 M PPY (Dt = 2 days)

10X

10X

10 M BZQ (Dt = 2 days)

10 M NMBPR -> 10 M BZQ (Dt = 2 days)

10X

10X

Figure 20. 48-Hour MCN experiment with Ir(III)-PPY vs. Ir(III)-BZQ on U-87 in
addition to pre-treatment with NMBPR Inhibitor (10X magnification)
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Contrasting results are obtained using Ir(III)-BZQ nucleoside. In this case,
microscope images (10X magnification) provided in Figure 20 demonstrate that pretreatment of U87 cells with 10 µM NBMPR does not block the uptake of low
concentrations of Ir(III)-BZQ nucleoside (10 µM). This is evident as the fluorescence
intensities of cells treated with 10 µM Ir(III)-BZQ nucleoside alone are nearly identical to
those obtained with NBMPR. This result indicates that Ir(III)-BZQ nucleoside does not
function as a substrate for hENT1 and differs from the related analog, Ir(III)-PPY
nucleoside, enters cells via active transport catalyzed by hENT1. Finally, the inability of
NBMPR to block the uptake of Ir(III)-BZQ nucleoside result confirms results provided in
Chapter 2 demonstrating that treatment with NBMPR does not produce a chemopreventive
effect against Ir(III)-BZQ nucleoside.
Figure 21 provides higher magnification images that further highlight the ability
of NBMPR to block the uptake of Ir(III)-PPY nucleoside but not the uptake of Ir(III)-BZQ
nucleoside into U87 cells. Collectively, these data indicate that hENT1 participates to
facilitate the entry of Ir(III)-PPY nucleoside into cells. In contrast, Ir(III)-BZQ nucleoside
does not appear to function as a substrate for hENT1. This dichotomy again highlights how
subtle alterations in structure can affect substrate utilization by nucleoside transporters.
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25 M PPY (Dt = 2 days)

10 M NMBPR -> 25 M PPY (Dt = 2 days)

40X

40X

10 M BZQ (Dt = 2 days)

10 M NMBPR -> 10 M BZQ (Dt = 2 days)

40X

40X

Figure 21. 48-Hour MCN Experiment: PPY vs. BZQ U-87 Pre-treatment with
NMBPR Inhibitor (40X magnification)
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Sub-cellular localization of Ir(III)-BZQ nucleoside.
Earlier, I presented data indicating that Ir(III)-BZQ nucleoside causes cell death via
the induction of apoptosis. To further examine this mechanism, microscopy techniques
were used to determine if Ir(III)-BZQ nucleoside localizes in the nucleus, mitochondria, or
other cellular organelles that are typically affiliated with apoptotic pathways. This analysis
is important as information regarding the localization of this metal-containing nucleoside
could provide insight into which cellular target(s) is(are) being affected to generate an
apoptotic response. Imaging experiments were performed treating U87 cells with 10 or 50
µM Ir(III)-BZQ nucleoside for time periods of 4 to 48 hours. At various time, cells were
then co-stained with DAPI or MitoPT-TMRE to identify various cellular organelles
(nucleus and mitochondria, respectively). Representative data provided in Figure 22 shows
the microscopy images of U87 cells treated with 10 or 50 µM Ir(III)-BZQ nucleoside for
48 hours and then stained with DAPI or MitoPT-TMRE to identify the nucleus and
mitochondria, respectively.
Cells treated with low concentrations of Ir(III)-BZQ nucleoside (10 µM) show
moderate levels of green fluorescence, indicating uptake of the metal-containing
nucleoside. The merged image of green fluorescence (reflecting the presence of Ir(III)BZQ nucleoside) coupled with DAPI staining (nuclear staining) does not show significant
accumulation of the nucleoside in the nucleus. Likewise, the merged image of green
fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled with MitoPTTMRE staining (mitochondria) also does not show significant accumulation of the
nucleoside in the mitochondria. Thus, under these conditions, it appears that the majority
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of fluorescence signal generated using low concentrations of Ir(III)-BZQ nucleoside is
confined to the cytoplasm.
Treatment with higher concentrations of Ir(III)-BZQ nucleoside (50 µM) produces
more pronounced effects. One obvious effect is that there are fewer cells present after
exposure to this higher concentration of nucleoside, and the lower cell number is consistent
with the dose-dependent cytotoxic effects of Ir(III)-BZQ nucleoside. Despite a reduction
in cell number, each remaining cell displays a significantly higher level of green
fluorescence that again represents the accumulation of the nucleoside within the cell.
Merged images again do not show significant co-localization of Ir(III)-BZQ nucleoside in
the nucleus of U87 cells treated for 48 hours. Instead, the merged image of green
fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled with MitoPTTMRE staining (mitochondria) shows significant accumulation of the nucleoside in these
organelles. The localization of Ir(III)-BZQ nucleoside in the mitochondria coupled with
its cytotoxic effects suggest that Ir(III)-BZQ nucleoside induces apoptosis by altering
mitochondrial activity. This could be achieved by interfering with enzymes involved in
ATP production or through the direct release of cytochrome c from the mitochondria.
Alternatively, the metal-containing nucleoside may exert an apoptotic effect by interacting
with nucleic acid, either RNA or DNA, inside the mitochondria. Future experiments are
planned to evaluate these potential mechanisms and are described in Chapter 4.
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Figure 22. Fluorescence microscopy images of Ir(III)-BZQ nucleoside uptake into U87
cells. U87 cells were treated with two different concentrations of Ir(III)-BZQ (10 and
50 µM) in the absence and presence of 2’-deoxyadenosine. Ir(III)-BZQ nucleoside
emits green fluorescence. Nuclei were stained with DAPI (blue), while mitochondria
were stained with MitoPT (red). The microscope magnification was 40X.
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Figure 23. 24-Hour MCN Experiment with U87 cells treated with Ir(III)-PPY vs.
Ir(III)-BZQ. (60X magnification)
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To further define the localization of Ir(III)-BZQ nucleoside in the mitochondria of
U87 cells, similar experiments using higher magnification to more accurately visualize the
nucleus and mitochondria. Preliminary results generated with the assistance of Dr. JungSuk Choi, a post-doctoral fellow in the Berdis lab, are provided in Figure 23. These images
taken at 60X magnification were obtained after treating U87 cells with variable
concentrations of Ir(III)-BZQ nucleoside (0, 10, 25, and 50 µM) for 48 hours. The merged
image of green fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled
with DAPI staining (nuclear staining) does not show significant co-localization. This result
again indicates that the metal-containing nucleoside does not appreciably accumulate in
the nucleus. Likewise, the merged image of green fluorescence (reflecting the presence of
Ir(III)-BZQ nucleoside) coupled with Mito-PT staining (staining of mitochondria) shows
some increase in co-localization, suggestive of accumulation of the nucleoside in the
mitochondria. Again, these results are preliminary and must be repeated to truly verify colocalization of Ir(III)-BZQ nucleoside in mitochondria. One complication of this
experiment is that there are significant morphological changes in U87 cells as the
concentration of Ir(III)-BZQ nucleoside is increased. These changes occur as the metalcontaining nucleoside induces apoptosis in a time-dependent manner. As such, additional
experiments will be performed at earlier time points (<24 hours) to avoid complications
associated with cell death that occur at high concentration of the metal-containing
nucleoside.
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Sub-cellular localization of Ir(III)-BZQ nucleoside is dependent upon nucleoside transport
activity.
Additional experiments were performed to validate that co-localization of Ir(III)BZQ nucleoside is dependent upon nucleoside transport activity. As illustrated in the
bottom panels of Figure 22, cells pre-treated with 200 µM 2’-deoxyadenosine have lower
levels of Ir(III)-BZQ nucleoside in the cytoplasm and mitochondria.

The lack of

localization occurs as adenosine blocks the uptake of the metal-containing nucleoside to
effectively lower its intracellular concentration. These results again confirm that transport
of Ir(III)-BZQ nucleoside across the cell membrane is dependent upon the activity a
nucleoside transporter. However, the inability of NBMPR to block the uptake of Ir(III)BZQ nucleoside suggests that hENT1 is not responsible. By inference, Ir(III)-BZQ
nucleoside enters U87 cell either via passive diffusion or through the activity of another
nucleoside transporter.

3.5

Discussion

The ability of chemotherapeutic nucleoside analogs to function as effective anticancer agents relies heavily upon their cellular transport. Because of their characteristic
overexpression of CNT and ENT membrane transporters, cancer cells can import higher
amount of nucleosides and deoxynucleoside which are required for increased levels of
DNA and RNA for storing and expressing genetic information. In general, the first step in
nucleoside metabolism is the active transport of a nucleoside across the cell membrane via
nucleoside transporters. Two major types of nucleoside transporters are used to facilitate
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the entry of natural nucleosides and their deoxynucleoside counterparts into brain cancer
cells. These include concentrative nucleoside transporters (CNTs) that are Na+-dependent
transporters that move substrates into cells against the concentration gradient. The second
class, equilibrative nucleoside transporters (ENTs), aid in the diffusion of nucleosides
across the cell membrane and operate bi-directionally according to the substrate
concentration gradient. In this study, I demonstrated that metal-containing nucleosides
accumulate within brain cancer cells in a dose and time dependent manner. This result
suggests that these analogs can be effectively used as surrogates to effectively quantify the
affinity of CNT and ENT membrane proteins for natural nucleosides through non-invasive
techniques employing standard fluorescence microscopy techniques. In addition, these
metal-containing nucleosides could be used to define the transport activity of nucleoside
analogs that are used as chemotherapeutic agents. Collectively, these studies described
here have addressed the selectivity of membrane nucleoside transporters to determine the
mechanism of how natural nucleosides are imported into cells.

Metal-Containing Nucleosides enter U87 Cells via Active Transport
The results here show that each metal-containing nucleoside enters U87 cells via
different mechanism. At face value, the ability of the natural nucleoside 2-deoxyadenosine, to block the uptake of either metal-containing nucleoside indicates the
involvement of an active transport system rather than simple passive diffusion. This active
transport system likely involves the catalytic activity of one or more nucleoside transporter.
This is clear since 2’-deoxyadenosine is a substrate for all hENT and hCNT family
members and thus functions as a broad spectrum inhibitor for the uptake of these metal98

containing nucleosides.(42, 140-142)

However, the use of NBMPR as a selective

inhibitor of hENT1 allowed for further determination for the involvement of this particular
transporter. Indeed, the data provided here indicates that Ir(III)-PPY nucleoside is
transported by hENT1 as pre-treatment with NBMPR blocks its uptake in both U87 cells
and KB3-1 cells. However, the same cannot be said for the uptake of Ir(III)-BZQ
nucleoside as pre-treatment with NBMPR does not block its uptake into U87 cells. Thus,
Ir(III)-BZQ nucleoside is most likely a poor substrate for hENT1 and must enter the cell
via the activity of another nucleoside transporter.

Subcellular localization
Eukaryotic cells possess several organelles including a nucleus, Golgi apparatus,
endoplasmic reticulum, lysosomes, and mitochondria. To function optimally, these
organelles are spatially separated from each other by membranes that prevent uncontrolled
movement of large (DNA, RNA, and proteins) and small (nucleosides/nucleotides)
molecules. One goal of this thesis is to understand how organelles function independently
and collectively. I hypothesize that this can be accomplished by accurately measuring the
influx and efflux of important cellular metabolites. Studies described here employing
metal-containing nucleosides have provided important information regarding the
movement of nucleoside surrogates into distinct organelles.
My studies focused on two specific organelles, the nucleus and the mitochondria.
The nucleus functions as the command center of a cell as it regulates many biological
processes, most notably gene expression and the integrity of the genome encoding these
genes. A double membrane encloses the nucleus and separates its contents from the
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cytoplasm. As such, the movement of large and small biomolecules required for RNA
(transcription) and DNA metabolism (replication, repair, transcription) is mediated by
pores that cross both membranes. The mechanism of this tightly regulated process is poorly
understood for lack of chemical entities that monitor macromolecules transport through the
nuclear pore complex.
Mitochondria are another important organelle as they supply the cell with ATP that
is needed for survival and proliferation. Often viewed as the cell’s “powerhouse,”
mitochondria can also play destructive roles by initiating events required for apoptosis.
Both processes are regulated by multiple signaling pathways, and I envision that the use of
the metal containing nucleoside, particularly Ir(III)-BZQ nucleoside, will provide a deeper
understanding of how nucleoside transport controls ATP synthesis and apoptosis.(143)
With KB3-1 cells as a model system, the Berdis lab previously used high-field
microscopy to demonstrate that Ir(III)-PPY nucleoside localizes inside organelles such as
the nucleus and/or mitochondria that are heavily involved in nucleoside metabolism.
Specifically, cells treated with 50 µM Ir(III)-PPY nucleoside showed high levels of green
fluorescence that reflects uptake of the biophotonic nucleoside. Merged images showed
co-localization of Ir(III)-PPY nucleoside with DAPI-stained nuclei, confirming that the
metal-containing nucleoside showed significant accumulation in the nucleus. Similar
experiments using MitoPT-TMRE to stain the mitochondria of KB3-1 cells also showed
that Ir(III)-PPY nucleoside co-localized in the mitochondria. Other staining experiments
indicated that Ir(III)-PPY nucleoside does not co-localize with other organelles including
cytoskeleton, Golgi, or lysosomes (data not shown).
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The results provided here demonstrate that Ir(III)-BZQ nucleoside localizes in the
cytoplasm and the mitochondria rather than the nucleus. On one hand, the localization of
Ir(III)-BZQ nucleoside in the mitochondria is consistent with its ability to induce apoptosis.
As described earlier, the mitochondria is not only the organelle responsible for ATP
production but it is also involved in regulating apoptosis. It is tempting to speculate that
Ir(III)-BZQ nucleoside affects mitochondrial integrity which produces an apoptotic
response due to the release of cyctochrome c, by inhibiting ATP synthesis, or a
combination of the two. Further experimentation is required to fully define these possible
mechanisms.

Regardless of these outcomes, it is very surprising that Ir(III)-BZQ

nucleoside and Ir(III)-PPY nucleoside show different localization patterns. In this regard,
Ir(III)-BZQ nucleoside appears to accumulate in the mitochondria while Ir(III)-PPY
nucleoside shows accumulation in both the mitochondria and nucleus.
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CHAPTER IV
CONCLUSIONS

There is an ongoing need for effective methods and devices to treat and diagnose many
types of cancer. Because proper treatment cannot be administered without an accurate
diagnosis, efforts to improve current diagnostic capabilities have become just as important
as treatment. It has been over 50 years since the World Health Organization (WHO) set
out to establish a tumor classification system that is accepted worldwide with the common
goal to clearly define histopathological and clinical diagnostic criteria and epidemiological
studies of cancerous tumors.(144, 145)

Tumor location, size, applied pressure, growth

rate, place of origin and cell type are amongst the varied factors considered when
classifying neoplasms and determine patient prognosis.

The research discussed herein

supports the development of improved diagnostic tools that were later found to possess
cytotoxic effects. This was also an effort to prove that the highly effective, emerging class
of nucleoside analogs used to treat many hematological cancers could be used to study the
biodisposition and mechanisms occurring inside tumor cells.
Given the success of conventional nucleoside analogs like fludarabine, there has
been a shift in the development of nucleoside analogs with more diverse functions. The
high cytotoxic effect of current chemotherapeutics like fludarabine to treat many forms of
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leukemia and gemcitabine against pancreatic cancer also support the notion of nucleoside
analogues as favorable candidates to promote the development of new chemotherapeutics
agents that are effective against neoplasms such as GBM. One approach commonly used
for the synthesis of new analogs of nucleosides is based on the augmentation of the ribose
sugar portion of the nucleoside. The analogs presented herein, however, will replace the
basic ring component of the chemotherapeutic analog, opposed to sugar substitution. The
affinity of these potential therapeutic compounds for specific cell types that overexpress
specific intramembranous proteins (CNT and ENT) also supported the hypothesis that
these new compounds may lead to potential agents to treat other types of cancers and
diseases that intrinsically possess the same characteristics. Such is the case with other
forms of cancer such as ovarian cancer and leukemia. Base on the realization that an
overexpression of nucleoside transporters is needed to support hyperproliferation of cancer
cells, an in depth look into the interactions of nucleoside analogs with nucleoside
transmembrane proteins has be evaluated.
Many of the problems encountered in the diagnosis and treatment of gliomas can
be confronted with a “theranostic” approach. Coined by the German scientist John
Funkhouser in 2002, the initial objective of theranostics was to describe a series of
diagnostic test to guide personalized therapies.(146)

Within the past 10 years, however,

the discipline has developed to include the dual ability of materials that can deliver a
therapeutic effect while simultaneously serving as diagnostic imaging agents. It has also
been hypothesized herein that these biophotonic probes utilize specific CNT and ENT
membrane proteins to enter hyperproliferative brain cancer cells. The therapeutic activity
of each of these MCNs against U87 glioblastomas cells has been measured using several
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biochemical methods.

Findings in this study also contribute to establishing a better

understanding of the proliferative nature of cancer cells, the identification of the selectivity
of specific nucleoside transporters, the mechanism and rate of cell death, and the effect of
MCNs when applied to non-cancerous cells models.
Amongst the original objectives of this project were studies of the pharmacokinetics
of metal containing nucleosides (MCNs) designed as luminescent photonic probes.
Because these nucleoside analogs have the added bonus of allowing sub cellular
localization imaging for diagnostic applications, exploiting the collective properties of
these biophores has disclosed the accumulation and metabolism of MCNs within specific
organelles and provided a means to probe intercellular interactions. Therefore, metal
containing nucleosides (MCNs) have the capability to ultimately function as therapeutic
and diagnostic agents, or “theranostic” agents.

This combined platform can eliminate

many of the pitfalls associated with the limited therapeutic and diagnostic tools for treating
orphan diseases such as highly fatal Glioblastoma Multiformae (GBM) brain tumors. Two
specific MCNs coined Ir(III)-PPY and Ir(III)-BZQ have been evaluated as a means to
identify the type of compounds limited by specific nucleoside transporter proteins. The
diagnostic capabilities of such compounds have been further exploited to visualize
intracellular localization and selectivity.
Initially, I sought to study the pharmacodynamics (what the drug does to the body)
via in-vivo / ex-vivo analysis with a cell model of the ATCC established brain cancer cell
line (U-87) for grade 4 glioblastoma brain tumors. These studies include the mechanisms
of cytotoxicity and effective concentrations required to be toxic in tumor cells vs. normal
cells (ATCC fibroblasts). Quantitative data has been presented examining the ability of
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metal-containing nucleosides to function as anti-cancer agents against glioblastoma, an
adherent cancer cell line. It is also important to state that although Ir(III)-BZQ expresses
an increased potency over Ir(III)-PPY, a higher potency may not be as efficient in clinical
applications and may lead to swelling and edema in shorter time frames than a less potent
therapeutic agent.
Analysis in a previous project focusing on the MCN Ir(III)-PPY concluded via cell
cycle analysis that this MCN acts as a kinase inhibitor and produces anti-cancer effects
against the established ovarian cancer, viral cell model (KB3-1). Cell-cycle progression is
also affected in both cervical cancer cells (KB3-1) and brain cancer cells (U87). Reasons
why the Ir(III)-PPY nucleoside has a more pronounced effect towards inducing apoptosis
in U87 cells compared to KB3-1 cells are still unclear and warrant further investigation, as
the underlying cellular mechanism for this difference is also unknown at this time.
In reference to the mechanism of cell death associated with MCNs, several
techniques including flow cytometry analysis and microscopy were conducted to test my
hypothesis. Microscopy studies measuring fluorescence associated with these analogs
demonstrate that both Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are taken up into
U87 cells in a time- and dose-dependent manner. In this respect, the cellular uptake of
Ir(III)-BZQ nucleoside is more efficient than that of Ir(III)-PPY nucleoside, and this
difference correlates with measured differences in their potency. Dual parameter flow
cytometry analyses validate that these nucleoside analogues cause apoptosis. Pre-treating
cells with known nucleoside transport inhibitors reduces the cytotoxicity of Ir(III)-PPY
nucleoside by blocking its cellular uptake. However, pre-treatment with NMBPR does not
block the cellular uptake of Ir(III)-BZQ nucleoside. These results indicate that cellular
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entry of Ir(III)-PPY nucleoside is mediated by the human equilibrative nucleoside
transporter one (hENT1) while transport of Ir(III)-BZQ nucleoside occurs via a different
pathway involving one or more other nucleoside transporters.
Cell cycle analysis results also provide evidence showing that the Ir(III)-PPY
nucleoside induces apoptosis, manifested by the increase in sub-G1. Significant increases
in the percentages of cell populations at S-phase and G2/M have also been observed.
Although these results suggest that Ir(III)-PPY nucleoside can affect cell-cycle progression
in diploid cells, similar results were observed in KB3-1 cells treated with Ir(III)-PPY
nucleoside. Collectively, however, conclusions may be drawn indicating that both Ir(III)PPY nucleoside and Ir(III)-BZQ nucleoside cause cell death via an apoptotic pathway as
opposed to necrosis.
Although structurally similar, the metal-containing nucleosides display unique
features that highlight how subtle permutations in structure can produce different
pharmacodynamic effects, This is evident as the potency of Ir(III)-BZQ nucleoside is ~8fold lower than Ir(III)-PPY nucleoside. This difference in potency reflects the ability of
Ir(III)-BZQ nucleoside to induce apoptosis at lower concentrations. In this case, dual
parameter FACS analyses measuring propidium iodide (PI) uptake and Alexa Fluor 488
Annexin V conjugate staining was used to demonstrate that Ir(III)-PPY nucleoside and
Ir(III)-BZQ nucleoside induce apoptosis rather than necrosis. These apoptotic effects are
both dose- and time-dependent, and this result is consistent with previous results measuring
cellular viability (vide supra). However, perhaps the most striking difference is the fact
Ir(III)-PPY nucleoside is transported by hENT1 while Ir(III)-BZQ, the more potent analog,
does not appear to an effective substrate for hENT1. The striking difference in the targeted
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pathways, however, require further studies to first confirm that Ir(III)-PPY nucleoside
appears to affect cell-cycle progression in U87 whereas Ir(III)-BZQ nucleoside has a
minimal effect, if any, on cell cycle progression.
Finally,

co-localization

studies

using

high-field

microscopy techniques

demonstrated that Ir(III)-PPY nucleoside accumulates in the nucleus and mitochondria of
these cancer cells. This last feature indicates that the metal-containing nucleoside is a novel
chemical probe that can measure nucleoside distribution at the cellular level.

Findings

within this project also indicate that cellular entry of Ir(III)-PPY nucleoside is mediated via
an active transport mechanism catalyzed by hENT1 (hENT1) while transport of Ir(III)BZQ nucleoside occurs via a different pathway involving one or more other nucleoside
transporters.

The use of the inhibitor NBMPR in pre-treatment has resulted in a

chemoprotective effective against Ir(III)-PPY nucleoside in KB3-1 cells. Surprisingly, the
structurally related analog, Ir(III)-BZQ nucleoside, however, does not appear to be
transported by hENT1 and therefore undergoes active transport by another nucleoside
transporter or via passive diffusion. Indeed, the data provided here indicates that Ir(III)PPY nucleoside is transported by hENT1 as pre-treatment with NBMPR blocks its uptake
in both U87 cells and KB3-1 cells. However, the same cannot be said for the uptake of
Ir(III)-BZQ nucleoside as pre-treatment with NBMPR does not block its uptake into U87
cells. Thus, Ir(III)-BZQ nucleoside is most likely a poor substrate for hENT1 and must
enter the cell via the activity of another nucleoside transporter.
Collectively, these data provide evidence for the development of a metal-containing
nucleoside that functions as a therapeutic agent against brain cancer that uses nucleoside
transporter activity to facilitate cellular entry. Subsequent analyses of the pharmacokinetic
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effects of MCN biodisposition support the use of MCNs as diagnostic probes via
fluorescence microscopy analysis of the transport and intracellular localization of these
luminophores across CNT and ENT nucleoside transporters.
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CHAPTER V
FUTURE DIRECTION

Although structure-activity relationships (SAR) of MCNs have not been determined, the
small structural features associated with the various ligands used to synthesize cyclometalated
iridium nucleoside analogs may be evaluated to alter potency or efficacy amongst this class of
analogs. Although many metals are associated with deleterious physiological effects, in specific
cases this toxicity can be tailored and targeted toward the treatment and diagnosis of cancer cells.
Combining this cytotoxicity along with properties such as Lewis acidity, redox reactivity, metal
chelating and coordinating ability and the proclivity to react with biological macromolecules can
collectively unleash lethal effects tumor cells.(147, 148)

Because of the versatility of metals in

comparison to carbon and small organic molecules, the formation of highly stable complexes
synthesized from ruthenium (Ru(II), osmium (Os(II), rhodium (Rh(III) and iridium (Ir(III) have
emerged as highly selective probes and protein inhibitors.(149)

The geometry of octahedral

metal coordination complexes, in particular, permit the synthesis of globular, rigid structures with
shapes similar to the stereochemical complexity of natural products.(150)
Similar to iridium, cyclometalated ring structures produced by ruthenium octahedral
coordination complexes have been successfully used to develop repair enzyme inhibitors as
potential chemotherapeutic agents with exceptional specificity for certain biological moieties.(151)
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Additional versatility has been observed in platinum cyclometalated octahedral complexes. Iridium
metal centers can be easier to synthesize than other metal complexes because they are not as
unstable or air sensitive. Recent studies reveal iridium complexes able to serve as asymmetric
catalysts by directly coordinating with biological substrates and a variety of chemically labile
ligands that promote configurationally stable metal complexes with increased selectivity.(152)
The potential of these and other metal complexes to serve as chemotherapeutic agents continues to
grow with the synthesis and discovery of more versatile metal chemotherapeutics.
As such, the affinity of CNT and ENT transporters substrates with specific functional
groups should be considered. The synthesis of these compounds is accomplished via a “click

chemistry” mechanism and has resulted in a library of ten metal containing nucleosides
synthesized to date (Figure 24). Initial factors such as availability during initial screening tests
limited the analysis of another MCN, Ir(III)-PBO more thoroughly. However, preliminary cell
viability studies with Ir(III)-PBO indicated that it may actually be the most potent of the first three
compounds studied. Because the molecular structures of Ir(III)-PPY and Ir(III)-BZQ were also
similar, in contrast with Ir(III)-PBO, these two MCNs were ultimately selected to facilitate this
study. Understanding the effects of specific functional groups attached to the cyclometalated
iridium will also help develop the medicinal chemistry approach to increase potency via specific
structural augmentations.
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Figure 24. A library of ten cyclometalated iridium metal containing nucleosides,
including Ir(III)-PPY and Ir(III)-BZQ, respectively, in the middle of the top
row.(132)
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To further conclude on the pharmacodynamic effects of MCNs on brain cancer cells, a
comparative analysis of the treatment of U-87 cells (along with additional cell models) treated with
MCNs and various know cell cycle inhibitors and chemotherapeutic agents should also be
conducted. During future experiments, other known chemotherapeutic agents and nucleoside
analogs such as pentostatin, mimosine, staurosporine cyclosporine and cisplatin may serve as
possible controls and variables to further indicate the mechanism of cell death via known
biomarkers associated with apoptotic character.
When determining the effective concentrations/doses that cause a therapeutic effect in
future experiments, discrepancies between flow cytometry data and cell viability data must be
addressed. For instance, the mitochondria can be used in the pharmacokinetic determination of the
rate of ATP depletion in the cells. The interaction of MCNs with mitochondrial pores may also be
evaluated and potentially visualized via high resolution microscopy to see if the MCN has
penetrated the mitochondrial matrix or if it is merely trapped between the inner and outer
membranes. Based on the conclusion of decreased ATP production after 48 hours, interval analysis
of ATP levels after 8, 16 and 24 hours will support the concentration and time dependent cytotoxic
effects of each MCN. This will also lead to the analysis of the use of mitochondrial membrane
transport proteins in MCN cytotoxicity.
In addition, specific assays used for measuring the ATP inside the mitochondria will also
pinpoint cellular mechanisms associated with dysfunctional mitochondria. When it comes to
measuring cell viability with greater sensitivity, one specific assay suggested is the ATP assay
using firefly luciferase; a light assay that is directly proportional to the change in light when
measuring specific protein levels required to produce light emission generated from the reaction of
oxygen and ATP. The measurement of ATP using firefly luciferase is the most commonly applies
method for estimating the number of viable cells. Contrary to the types of assays previously
mentioned, the ATP assay is the fastest cell viability assay to use, although generally much more
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expensive.

With the elimination of incubation time required before analysis, the resulting

luminescent signal typically glows for approximately five hours.(153)
The overexpression of key nucleoside transporters is a potential biomarker for the
treatment of many types of cancer with nucleoside analogs. Western Blot analysis can be used to
determine protein levels of CNT and ENT proteins in various cell types. Another method to
evaluate the activity of transporter proteins is the use of siRNA to knock down the specific protein
of interest. The interaction of substrates and inhibitors specific to individual transporters, such as
NMBPR, also generate similar results. Using the ubiquitously transported nucleoside adenosine,
for instance, was found to be a key way to prove the uptake of MCNs via nucleoside transporters,
opposed to the siRNA analysis of each of the seven (7) individual isoforms of CNT and ENT
proteins independently.
Theranostics have the potential to revolutionize medicine and healthcare. The reasons for
the especially high cost of healthcare in the US can be attributed to a number of factors ranging
from inappropriate healthcare and the rising cost of medical technology and prescription drugs. As
the landscape of molecular diagnostics continues to change, a new focus on personalized medicine
has emerged and continues to be driven by numerous factors.(154)

The current lack of effective

diagnostics tools, consumers demanding more affordable medicines and less side effects and the
aging baby boomer population are all contributing factors.

Clinicians and Pharmaceutical

companies alike can benefit from using the unique theranostics platform to improve the outcome
of patients.(155)

Ultimately, however, in order for the future of theranostics to flourish, there

must be a bridge in the gap between the overlapping disciplines of organic and inorganic synthesis
with medicinal and clinical chemists, radiologist and oncologist to optimize the capabilities of
improved molecular, therapeutic and diagnostic tools.
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